<full-text-retrieval-response xmlns="http://www.elsevier.com/xml/svapi/article/dtd" xmlns:bk="http://www.elsevier.com/xml/bk/dtd" xmlns:cals="http://www.elsevier.com/xml/common/cals/dtd" xmlns:ce="http://www.elsevier.com/xml/common/dtd" xmlns:ja="http://www.elsevier.com/xml/ja/dtd" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:sa="http://www.elsevier.com/xml/common/struct-aff/dtd" xmlns:sb="http://www.elsevier.com/xml/common/struct-bib/dtd" xmlns:tb="http://www.elsevier.com/xml/common/table/dtd" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xocs="http://www.elsevier.com/xml/xocs/dtd" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:prism="http://prismstandard.org/namespaces/basic/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><coredata><prism:url>https://api.elsevier.com/content/article/pii/S1359644620302300</prism:url><dc:identifier>doi:10.1016/j.drudis.2020.06.005</dc:identifier><eid>1-s2.0-S1359644620302300</eid><prism:doi>10.1016/j.drudis.2020.06.005</prism:doi><pii>S1359-6446(20)30230-0</pii><dc:title>Targeting post-translational modification of transcription factors as cancer therapy </dc:title><prism:publicationName>Drug Discovery Today</prism:publicationname><prism:aggregationType>Journal</prism:aggregationtype><pubType>rev</pubtype><prism:issn>13596446</prism:issn><prism:volume>25</prism:volume><prism:issueIdentifier>8</prism:issueidentifier><prism:startingPage>1502</prism:startingpage><prism:endingPage>1512</prism:endingpage><prism:pageRange>1502-1512</prism:pagerange><prism:number>8</prism:number><dc:format>text/xml</dc:format><prism:coverDate>2020-08-31</prism:coverdate><prism:coverDisplayDate>August 2020</prism:coverdisplaydate><prism:copyright>© 2020 Elsevier Ltd. All rights reserved.</prism:copyright><prism:publisher>Elsevier Ltd.</prism:publisher><dc:creator>Qian, Meijia</dc:creator><dc:creator>Yan, Fangjie</dc:creator><dc:creator>Yuan, Tao</dc:creator><dc:creator>Yang, Bo</dc:creator><dc:creator>He, Qiaojun</dc:creator><dc:creator>Zhu, Hong</dc:creator><dc:description>
                  Dysregulated transcription factors (TFs) fuel aberrant gene expression networks, resulting in cell overproliferation, migration, and immunosuppression. Given that TFs are regarded to have vital roles in tumors, various approaches are exploited to modulate their activities. Nevertheless, except for some ligand-binding nuclear receptors, most TFs are still considered ‘undruggable’ targets. Responding to extra- or intracellular stimuli, TFs are decorated with an array of post-translational modifications (PTMs) to regulate their subcellular localizations, protein–protein/DNA interactions, and stability. These PTMs orchestrate the multiple functions of TFs, thus offering numerous potential targets. In this review, we systematically review emerging concepts and effective agents in PTMs-associated TF-targeting, which could provide paradigms for cancer treatment.
               </dc:description><openaccess>0</openaccess><openaccessArticle>false</openaccessarticle><openaccessType/></openaccesstype><openArchiveArticle>false</openarchivearticle><openaccessSponsorName/></openaccesssponsorname><openaccessSponsorType/></openaccesssponsortype><openaccessUserLicense/></openaccessuserlicense><link href="https://api.elsevier.com/content/article/pii/S1359644620302300" rel="self"/></link><link href="https://www.sciencedirect.com/science/article/pii/S1359644620302300" rel="scidir"/></link></coredata><objects><object ref="gr1" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="836" height="430" size="90616">https://api.elsevier.com/content/object/eid/1-s2.0-S1359644620302300-gr1.jpg?httpAccept=%2A%2F%2A</object><object ref="gr2" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="836" height="471" size="82516">https://api.elsevier.com/content/object/eid/1-s2.0-S1359644620302300-gr2.jpg?httpAccept=%2A%2F%2A</object><object ref="gr3" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="836" height="567" size="122416">https://api.elsevier.com/content/object/eid/1-s2.0-S1359644620302300-gr3.jpg?httpAccept=%2A%2F%2A</object><object ref="gr4" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="836" height="541" size="112050">https://api.elsevier.com/content/object/eid/1-s2.0-S1359644620302300-gr4.jpg?httpAccept=%2A%2F%2A</object><object ref="gr1" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="113" size="13659">https://api.elsevier.com/content/object/eid/1-s2.0-S1359644620302300-gr1.sml?httpAccept=%2A%2F%2A</object><object ref="gr2" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="123" size="15462">https://api.elsevier.com/content/object/eid/1-s2.0-S1359644620302300-gr2.sml?httpAccept=%2A%2F%2A</object><object ref="gr3" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="149" size="17970">https://api.elsevier.com/content/object/eid/1-s2.0-S1359644620302300-gr3.sml?httpAccept=%2A%2F%2A</object><object ref="gr4" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="142" size="16582">https://api.elsevier.com/content/object/eid/1-s2.0-S1359644620302300-gr4.sml?httpAccept=%2A%2F%2A</object><object ref="gr1" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="3703" height="1904" size="755072">https://api.elsevier.com/content/object/eid/1-s2.0-S1359644620302300-gr1_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr2" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="3703" height="2088" size="730252">https://api.elsevier.com/content/object/eid/1-s2.0-S1359644620302300-gr2_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr3" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="3703" height="2513" size="1090915">https://api.elsevier.com/content/object/eid/1-s2.0-S1359644620302300-gr3_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr4" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="3703" height="2397" size="943489">https://api.elsevier.com/content/object/eid/1-s2.0-S1359644620302300-gr4_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="am" category="standard" type="AAM-PDF" multimediatype="Acrobat PDF file" mimetype="application/pdf" size="4337451">https://api.elsevier.com/content/object/eid/1-s2.0-S1359644620302300-am.pdf?httpAccept=%2A%2F%2A</object></objects><scopus-id>85086925182</scopus-id><scopus-eid>2-s2.0-85086925182</scopus-eid><pubmed-id>32540433</pubmed-id><link href="https://api.elsevier.com/content/abstract/scopus_id/85086925182" rel="abstract"/></link><originalText><xocs:doc xsi:schemaLocation="http://www.elsevier.com/xml/xocs/dtd http://null/schema/dtds/document/fulltext/xcr/xocs-article.xsd"><xocs:meta xmlns:xoe="http://www.elsevier.com/xml/xoe/dtd">
      <xocs:content-family>serial</xocs:content-family>
      <xocs:content-type>JL</xocs:content-type>
      <xocs:cid>271275</xocs:cid>
      <xocs:ssids>
         <xocs:ssid type="alllist">291210</xocs:ssid>
         <xocs:ssid type="subj">291727</xocs:ssid>
         <xocs:ssid type="subj">291850</xocs:ssid>
         <xocs:ssid type="subj">291928</xocs:ssid>
         <xocs:ssid type="content">31</xocs:ssid>
      </xocs:ssids>
      <xocs:srctitle>Drug Discovery Today</xocs:srctitle>
      <xocs:normalized-srctitle>DRUGDISCOVERYTODAY</xocs:normalized-srctitle>
      <xocs:orig-load-date yyyymmdd="20200612">2020-06-12</xocs:orig-load-date>
      <xocs:available-online-date yyyymmdd="20200612">2020-06-12</xocs:available-online-date>
      <xocs:vor-load-date yyyymmdd="20200818">2020-08-18</xocs:vor-load-date>
      <xocs:vor-available-online-date yyyymmdd="20200818">2020-08-18</xocs:vor-available-online-date>
      <xocs:ew-transaction-id>2021-07-14T00:52:31</xocs:ew-transaction-id>
      <xocs:eid>1-s2.0-S1359644620302300</xocs:eid>
      <xocs:pii-formatted>S1359-6446(20)30230-0</xocs:pii-formatted>
      <xocs:pii-unformatted>S1359644620302300</xocs:pii-unformatted>
      <xocs:doi>10.1016/j.drudis.2020.06.005</xocs:doi>
      <xocs:item-stage>S300</xocs:item-stage>
      <xocs:item-version-number>S300.2</xocs:item-version-number>
      <xocs:item-weight>FULL-TEXT</xocs:item-weight>
      <xocs:hub-eid>1-s2.0-S1359644620X00092</xocs:hub-eid>
      <xocs:timestamp yyyymmdd="20210714">2021-07-14T00:00:11.156898Z</xocs:timestamp>
      <xocs:dco>0</xocs:dco>
      <xocs:tomb>0</xocs:tomb>
      <xocs:date-search-begin>20200801</xocs:date-search-begin>
      <xocs:date-search-end>20200831</xocs:date-search-end>
      <xocs:year-nav>2020</xocs:year-nav>
      <xocs:indexeddate epoch="1591975373">2020-06-12T15:22:53.961393Z</xocs:indexeddate>
      <xocs:articleinfo>articleinfo articletitlenorm authfirstinitialnorm authfirstsurnamenorm cid cids contenttype copyright crossmark dateloaded dateloadedtxt datesearch datesort dateupdated dco docsubtype doctype doi eid ewtransactionid hubeid indexeddate issfirst issn issnnorm issuelist itemstage itemtransactionid itemweight openaccess openarchive pg pgfirst pglast pii piinorm pubdateend pubdatestart pubdatetxt pubyr sectiontitle sortorder srctitle srctitlenorm srctype ssids alllist content subj subheadings tomb volfirst volissue volumelist webpdf webpdfpagecount yearnav figure table body acknowledge affil articletitle auth authfirstini authfull authlast grantnumber grantsponsor grantsponsorid highlightsabst orcid primabst pubtype ref</xocs:articleinfo>
      <xocs:issns>
         <xocs:issn-primary-formatted>1359-6446</xocs:issn-primary-formatted>
         <xocs:issn-primary-unformatted>13596446</xocs:issn-primary-unformatted>
      </xocs:issns>
      <xocs:crossmark is-crossmark="1">true</xocs:crossmark>
      <xocs:vol-first>25</xocs:vol-first>
      <xocs:volume-list>
         <xocs:volume>25</xocs:volume>
      </xocs:volume-list>
      <xocs:iss-first>8</xocs:iss-first>
      <xocs:issue-list>
         <xocs:issue>8</xocs:issue>
      </xocs:issue-list>
      <xocs:vol-iss-suppl-text>Volume 25, Issue 8</xocs:vol-iss-suppl-text>
      <xocs:sort-order>23</xocs:sort-order>
      <xocs:first-fp>1502</xocs:first-fp>
      <xocs:last-lp>1512</xocs:last-lp>
      <xocs:pages>
         <xocs:first-page>1502</xocs:first-page>
         <xocs:last-page>1512</xocs:last-page>
      </xocs:pages>
      <xocs:cover-date-orig>
         <xocs:start-date>202008</xocs:start-date>
      </xocs:cover-date-orig>
      <xocs:cover-date-text>August 2020</xocs:cover-date-text>
      <xocs:cover-date-start>2020-08-01</xocs:cover-date-start>
      <xocs:cover-date-end>2020-08-31</xocs:cover-date-end>
      <xocs:cover-date-year>2020</xocs:cover-date-year>
      <xocs:hub-sec>
         <xocs:hub-sec-title>REVIEWS</xocs:hub-sec-title>
         <xocs:hub-sec>
            <xocs:hub-sec-title>Post Screen</xocs:hub-sec-title>
         </xocs:hub-sec>
      </xocs:hub-sec>
      <xocs:document-type>article</xocs:document-type>
      <xocs:document-subtype>rev</xocs:document-subtype>
      <xocs:copyright-line>© 2020 Elsevier Ltd. All rights reserved.</xocs:copyright-line>
      <xocs:normalized-article-title>TARGETINGPOSTTRANSLATIONALMODIFICATIONTRANSCRIPTIONFACTORSCANCERTHERAPY</xocs:normalized-article-title>
      <xocs:normalized-first-auth-surname>QIAN</xocs:normalized-first-auth-surname>
      <xocs:normalized-first-auth-initial>M</xocs:normalized-first-auth-initial>
      <xocs:item-toc>
         <xocs:item-toc-entry ref-elem="ce:sections">
            <xocs:item-toc-section-title>Introduction</xocs:item-toc-section-title>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:sections">
            <xocs:item-toc-section-title>Targeting TF ubiquitination</xocs:item-toc-section-title>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-section-title>Interfering with TF ubiquitination for proteolytic regulation</xocs:item-toc-section-title>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-section-title>Modulating proteasome degradation through E3 ligase</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-section-title>Destabilization of TFs by inhibiting DUBs</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-section-title>PROTAC</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-section-title>Promoting proteolysis by small-molecule binding to TFs</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-section-title>Interfering with nonproteolytic ubiquitination of TFs</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:sections">
            <xocs:item-toc-section-title>Targeting TF phosphorylation</xocs:item-toc-section-title>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-section-title>Inhibiting phosphorylation to attenuate TFs activity</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-section-title>Promoting phosphorylation to inhibit TF activity</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:sections">
            <xocs:item-toc-section-title>Targeting TF acetylation</xocs:item-toc-section-title>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:sections">
            <xocs:item-toc-section-title>Targeting TF methylation</xocs:item-toc-section-title>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:sections">
            <xocs:item-toc-section-title>Targeting TF sumoylation</xocs:item-toc-section-title>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:sections">
            <xocs:item-toc-section-title>Concluding remarks and future perspectives</xocs:item-toc-section-title>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:sections">
            <xocs:item-toc-section-title>Declaration of Competing Interest</xocs:item-toc-section-title>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:acknowledgment">
            <xocs:item-toc-section-title>Acknowledgments</xocs:item-toc-section-title>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:bibliography">
            <xocs:item-toc-section-title>References</xocs:item-toc-section-title>
         </xocs:item-toc-entry>
      </xocs:item-toc>
      <xocs:references>
         <xocs:ref-info refid="sbref0005">
            <xocs:ref-normalized-surname>BUSHWELLER</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2019</xocs:ref-pub-year>
            <xocs:ref-first-fp>611</xocs:ref-first-fp>
            <xocs:ref-last-lp>624</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0010">
            <xocs:ref-normalized-surname>BRADNER</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2017</xocs:ref-pub-year>
            <xocs:ref-first-fp>629</xocs:ref-first-fp>
            <xocs:ref-last-lp>643</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0015">
            <xocs:ref-normalized-surname>HAGENBUCHNER</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2016</xocs:ref-pub-year>
            <xocs:ref-first-fp>1</xocs:ref-first-fp>
            <xocs:ref-last-lp>13</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0020">
            <xocs:ref-normalized-surname>FILTZ</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2014</xocs:ref-pub-year>
            <xocs:ref-first-fp>76</xocs:ref-first-fp>
            <xocs:ref-last-lp>85</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>T</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0025">
            <xocs:ref-normalized-surname>POPOVIC</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2014</xocs:ref-pub-year>
            <xocs:ref-first-fp>1242</xocs:ref-first-fp>
            <xocs:ref-last-lp>1253</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>D</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0030">
            <xocs:ref-normalized-surname>LIU</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2015</xocs:ref-pub-year>
            <xocs:ref-first-fp>50</xocs:ref-first-fp>
            <xocs:ref-last-lp>60</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0035">
            <xocs:ref-normalized-surname>GALLO</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2017</xocs:ref-pub-year>
            <xocs:ref-first-fp>634</xocs:ref-first-fp>
            <xocs:ref-last-lp>648</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>L</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0040">
            <xocs:ref-normalized-surname>WANG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2017</xocs:ref-pub-year>
            <xocs:ref-first-fp>683</xocs:ref-first-fp>
            <xocs:ref-last-lp>702</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>D</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0045">
            <xocs:ref-normalized-surname>LEMOS</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2016</xocs:ref-pub-year>
            <xocs:ref-first-fp>789</xocs:ref-first-fp>
            <xocs:ref-last-lp>844</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>A</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0050">
            <xocs:ref-normalized-surname>WANG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2014</xocs:ref-pub-year>
            <xocs:ref-first-fp>5086</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>W</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0055">
            <xocs:ref-normalized-surname>ANDREEFF</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2016</xocs:ref-pub-year>
            <xocs:ref-first-fp>868</xocs:ref-first-fp>
            <xocs:ref-last-lp>876</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0060">
            <xocs:ref-normalized-surname>HER</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2018</xocs:ref-pub-year>
            <xocs:ref-first-fp>792</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>N</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0065">
            <xocs:ref-normalized-surname>REUTHER</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2018</xocs:ref-pub-year>
            <xocs:ref-first-fp>1</xocs:ref-first-fp>
            <xocs:ref-last-lp>19</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>C</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0070">
            <xocs:ref-normalized-surname>YING</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2016</xocs:ref-pub-year>
            <xocs:ref-first-fp>4358</xocs:ref-first-fp>
            <xocs:ref-last-lp>4367</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0075">
            <xocs:ref-normalized-surname>GANDOLFI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2017</xocs:ref-pub-year>
            <xocs:ref-first-fp>561</xocs:ref-first-fp>
            <xocs:ref-last-lp>584</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>S</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0080">
            <xocs:ref-normalized-surname>DAS</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2017</xocs:ref-pub-year>
            <xocs:ref-first-fp>4280</xocs:ref-first-fp>
            <xocs:ref-last-lp>4289</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>D</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0085">
            <xocs:ref-normalized-surname>LEE</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2016</xocs:ref-pub-year>
            <xocs:ref-first-fp>37</xocs:ref-first-fp>
            <xocs:ref-last-lp>47</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0090">
            <xocs:ref-normalized-surname>WANG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2016</xocs:ref-pub-year>
            <xocs:ref-first-fp>99</xocs:ref-first-fp>
            <xocs:ref-last-lp>112</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>L</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0095">
            <xocs:ref-normalized-surname>LIU</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2019</xocs:ref-pub-year>
            <xocs:ref-first-fp>4572</xocs:ref-first-fp>
            <xocs:ref-last-lp>4582</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>Y</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0100">
            <xocs:ref-normalized-surname>YUAN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2020</xocs:ref-pub-year>
            <xocs:ref-first-fp>197</xocs:ref-first-fp>
            <xocs:ref-last-lp>210</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>T</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0105">
            <xocs:ref-normalized-surname>HARRIGAN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2018</xocs:ref-pub-year>
            <xocs:ref-first-fp>57</xocs:ref-first-fp>
            <xocs:ref-last-lp>78</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0110">
            <xocs:ref-normalized-surname>VERMA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2020</xocs:ref-pub-year>
            <xocs:ref-first-fp>446</xocs:ref-first-fp>
            <xocs:ref-last-lp>460</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>R</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0115">
            <xocs:ref-normalized-surname>WANG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2020</xocs:ref-pub-year>
            <xocs:ref-first-fp>207</xocs:ref-first-fp>
            <xocs:ref-last-lp>238</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>Y</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0120">
            <xocs:ref-normalized-surname>SUN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2018</xocs:ref-pub-year>
            <xocs:ref-first-fp>343</xocs:ref-first-fp>
            <xocs:ref-last-lp>352</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>B</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0125">
            <xocs:ref-normalized-surname>ARVINAS</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2019</xocs:ref-pub-year>
            <xocs:ref-normalized-srctitle>APHASE1CLINICALTRIALARV110INPATIENTSMETASTATICCASTRATIONRESISTANTPROSTATECANCERMCRPC</xocs:ref-normalized-srctitle>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0130">
            <xocs:ref-normalized-surname>ARVINAS</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2020</xocs:ref-pub-year>
            <xocs:ref-normalized-srctitle>ARV471ERTARGETINGPROTEINDEGRADERFORBREASTCANCER</xocs:ref-normalized-srctitle>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0135">
            <xocs:ref-normalized-surname>SCUDELLARI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2019</xocs:ref-pub-year>
            <xocs:ref-first-fp>298</xocs:ref-first-fp>
            <xocs:ref-last-lp>300</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0140">
            <xocs:ref-normalized-surname>BAI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2019</xocs:ref-pub-year>
            <xocs:ref-first-fp>498</xocs:ref-first-fp>
            <xocs:ref-last-lp>511</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>L</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0145">
            <xocs:ref-normalized-surname>HEPPLER</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2019</xocs:ref-pub-year>
            <xocs:ref-first-fp>459</xocs:ref-first-fp>
            <xocs:ref-last-lp>461</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>L</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0150">
            <xocs:ref-normalized-surname>CICCONI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2018</xocs:ref-pub-year>
            <xocs:ref-first-fp>1671</xocs:ref-first-fp>
            <xocs:ref-last-lp>1678</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>L</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0155">
            <xocs:ref-normalized-surname>KRONKE</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2014</xocs:ref-pub-year>
            <xocs:ref-first-fp>301</xocs:ref-first-fp>
            <xocs:ref-last-lp>305</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0160">
            <xocs:ref-normalized-surname>SIEVERS</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2018</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>Q</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0165">
            <xocs:ref-normalized-surname>DIMOPOULOS</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2016</xocs:ref-pub-year>
            <xocs:ref-first-fp>497</xocs:ref-first-fp>
            <xocs:ref-last-lp>503</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0170">
            <xocs:ref-normalized-surname>GLORIAN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2017</xocs:ref-pub-year>
            <xocs:ref-first-fp>e2816</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>V</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0175">
            <xocs:ref-normalized-surname>YAO</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2018</xocs:ref-pub-year>
            <xocs:ref-first-fp>2269</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>F</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0180">
            <xocs:ref-normalized-surname>JANG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2019</xocs:ref-pub-year>
            <xocs:ref-first-fp>278</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>H</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0185">
            <xocs:ref-normalized-surname>NAGATHIHALLI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2015</xocs:ref-pub-year>
            <xocs:ref-first-fp>1932</xocs:ref-first-fp>
            <xocs:ref-last-lp>1943</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>N</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0190">
            <xocs:ref-normalized-surname>HA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2016</xocs:ref-pub-year>
            <xocs:ref-first-fp>1971</xocs:ref-first-fp>
            <xocs:ref-last-lp>1990</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0195">
            <xocs:ref-normalized-surname>LU</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2014</xocs:ref-pub-year>
            <xocs:ref-first-fp>222</xocs:ref-first-fp>
            <xocs:ref-last-lp>234</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>G</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0200">
            <xocs:ref-normalized-surname>LIAO</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2019</xocs:ref-pub-year>
            <xocs:ref-first-fp>6723</xocs:ref-first-fp>
            <xocs:ref-last-lp>6736</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>S</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0205">
            <xocs:ref-normalized-surname>WU</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2014</xocs:ref-pub-year>
            <xocs:ref-first-fp>82</xocs:ref-first-fp>
            <xocs:ref-last-lp>91</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>Y</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0210">
            <xocs:ref-normalized-surname>MAUGERISACCA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2018</xocs:ref-pub-year>
            <xocs:ref-first-fp>60</xocs:ref-first-fp>
            <xocs:ref-last-lp>72</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0215">
            <xocs:ref-normalized-surname>DAI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2016</xocs:ref-pub-year>
            <xocs:ref-first-fp>6933</xocs:ref-first-fp>
            <xocs:ref-last-lp>6947</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>X</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0220">
            <xocs:ref-normalized-surname>ZHOU</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2016</xocs:ref-pub-year>
            <xocs:ref-first-fp>30483</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>T</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0225">
            <xocs:ref-normalized-surname>ZHU</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2018</xocs:ref-pub-year>
            <xocs:ref-first-fp>3995</xocs:ref-first-fp>
            <xocs:ref-last-lp>4006</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>H</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0230">
            <xocs:ref-normalized-surname>SU</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2018</xocs:ref-pub-year>
            <xocs:ref-first-fp>1398</xocs:ref-first-fp>
            <xocs:ref-last-lp>1419</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>Y</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0235">
            <xocs:ref-normalized-surname>HAN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2019</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>H</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0240">
            <xocs:ref-normalized-surname>MRAKOVCIC</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2019</xocs:ref-pub-year>
            <xocs:ref-first-fp>2415</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0245">
            <xocs:ref-normalized-surname>WANG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2016</xocs:ref-pub-year>
            <xocs:ref-first-fp>118</xocs:ref-first-fp>
            <xocs:ref-last-lp>122</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>D</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0250">
            <xocs:ref-normalized-surname>BROOKS</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2011</xocs:ref-pub-year>
            <xocs:ref-first-fp>456</xocs:ref-first-fp>
            <xocs:ref-last-lp>462</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>C</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0255">
            <xocs:ref-normalized-surname>WANG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2016</xocs:ref-pub-year>
            <xocs:ref-first-fp>366</xocs:ref-first-fp>
            <xocs:ref-last-lp>373</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>S</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0260">
            <xocs:ref-normalized-surname>DE</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2018</xocs:ref-pub-year>
            <xocs:ref-first-fp>2743</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>U</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0265">
            <xocs:ref-normalized-surname>ZHENG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2017</xocs:ref-pub-year>
            <xocs:ref-first-fp>4342</xocs:ref-first-fp>
            <xocs:ref-last-lp>4354</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>S</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0270">
            <xocs:ref-normalized-surname>HSU</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2014</xocs:ref-pub-year>
            <xocs:ref-first-fp>534</xocs:ref-first-fp>
            <xocs:ref-last-lp>548</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>D</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0275">
            <xocs:ref-normalized-surname>NEBBIOS</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2017</xocs:ref-pub-year>
            <xocs:ref-first-fp>2542</xocs:ref-first-fp>
            <xocs:ref-last-lp>2555</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>O</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0280">
            <xocs:ref-normalized-surname>HAMAMOTO</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2015</xocs:ref-pub-year>
            <xocs:ref-first-fp>110</xocs:ref-first-fp>
            <xocs:ref-last-lp>124</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>R</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0285">
            <xocs:ref-normalized-surname>KEATING</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2013</xocs:ref-pub-year>
            <xocs:ref-first-fp>361</xocs:ref-first-fp>
            <xocs:ref-last-lp>372</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>S</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0290">
            <xocs:ref-normalized-surname>SARRIS</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2014</xocs:ref-pub-year>
            <xocs:ref-first-fp>1207</xocs:ref-first-fp>
            <xocs:ref-last-lp>1217</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0295">
            <xocs:ref-normalized-surname>LIU</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2015</xocs:ref-pub-year>
            <xocs:ref-first-fp>881</xocs:ref-first-fp>
            <xocs:ref-last-lp>891</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>Q</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0300">
            <xocs:ref-normalized-surname>MENG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2015</xocs:ref-pub-year>
            <xocs:ref-first-fp>8166</xocs:ref-first-fp>
            <xocs:ref-last-lp>8181</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>F</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0305">
            <xocs:ref-normalized-surname>CHAE</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2019</xocs:ref-pub-year>
            <xocs:ref-first-fp>1692</xocs:ref-first-fp>
            <xocs:ref-last-lp>1705</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>Y</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0310">
            <xocs:ref-normalized-surname>DAWSON</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2017</xocs:ref-pub-year>
            <xocs:ref-first-fp>1147</xocs:ref-first-fp>
            <xocs:ref-last-lp>1152</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0315">
            <xocs:ref-normalized-surname>SEELER</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2017</xocs:ref-pub-year>
            <xocs:ref-first-fp>184</xocs:ref-first-fp>
            <xocs:ref-last-lp>197</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0320">
            <xocs:ref-normalized-surname>ABLAIN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2011</xocs:ref-pub-year>
            <xocs:ref-first-fp>117</xocs:ref-first-fp>
            <xocs:ref-last-lp>127</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0325">
            <xocs:ref-normalized-surname>KESSLER</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2012</xocs:ref-pub-year>
            <xocs:ref-first-fp>348</xocs:ref-first-fp>
            <xocs:ref-last-lp>353</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0330">
            <xocs:ref-normalized-surname>HE</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2017</xocs:ref-pub-year>
            <xocs:ref-first-fp>1164</xocs:ref-first-fp>
            <xocs:ref-last-lp>1171</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>X</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0335">
            <xocs:ref-normalized-surname>GONZALEZPRIETO</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2015</xocs:ref-pub-year>
            <xocs:ref-first-fp>1859</xocs:ref-first-fp>
            <xocs:ref-last-lp>1872</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>R</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0340">
            <xocs:ref-normalized-surname>LI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2019</xocs:ref-pub-year>
            <xocs:ref-first-fp>278</xocs:ref-first-fp>
            <xocs:ref-last-lp>288</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>Y</xocs:ref-normalized-initial>
         </xocs:ref-info>
      </xocs:references>
      <xocs:refkeys>
         <xocs:refkey3>QIANX2020X1502</xocs:refkey3>
         <xocs:refkey4lp>QIANX2020X1502X1512</xocs:refkey4lp>
         <xocs:refkey4ai>QIANX2020X1502XM</xocs:refkey4ai>
         <xocs:refkey5>QIANX2020X1502X1512XM</xocs:refkey5>
      </xocs:refkeys>
      <xocs:open-access>
         <xocs:oa-article-status is-open-access="0" is-open-archive="0"/></xocs:oa-article-status>
      </xocs:open-access>
      <xocs:open-research>
         <xocs:or-embargo-opening-date>2021-08-18T00:00:00.000Z</xocs:or-embargo-opening-date>
      </xocs:open-research>
      <xocs:self-archiving>
         <xocs:sa-start-date>2021-08-18T00:00:00.000Z</xocs:sa-start-date>
         <xocs:sa-user-license>http://creativecommons.org/licenses/by-nc-nd/4.0/</xocs:sa-user-license>
      </xocs:self-archiving>
      <xocs:copyright-info>
         <xocs:cp-notices>
            <xocs:cp-notice lang="en">© 2020 Elsevier Ltd. All rights reserved.</xocs:cp-notice>
         </xocs:cp-notices>
      </xocs:copyright-info>
      <xocs:funding-list has-funding-info="1">
         <xocs:funding-addon-generated-timestamp>2021-06-04T21:53:38.571Z</xocs:funding-addon-generated-timestamp>
         <xocs:funding-addon-type>http://vtw.elsevier.com/data/voc/AddOnTypes/50.7/aggregated-refined</xocs:funding-addon-type>
         <xocs:funding>
            <xocs:funding-agency-matched-string>National Natural Science Foundation of China</xocs:funding-agency-matched-string>
            <xocs:funding-id>81830107</xocs:funding-id>
            <xocs:funding-id>81973349</xocs:funding-id>
            <xocs:funding-agency-acronym>NSFC</xocs:funding-agency-acronym>
            <xocs:funding-agency>National Natural Science Foundation of China</xocs:funding-agency>
            <xocs:funding-agency-id>http://data.elsevier.com/vocabulary/SciValFunders/501100001809</xocs:funding-agency-id>
            <xocs:funding-agency-country>http://sws.geonames.org/1814991/</xocs:funding-agency-country>
         </xocs:funding>
         <xocs:funding>
            <xocs:funding-agency-matched-string>Natural Science Foundation of Zhejiang Province</xocs:funding-agency-matched-string>
            <xocs:funding-id>LR19H310002</xocs:funding-id>
            <xocs:funding-agency-acronym>ZJNSF</xocs:funding-agency-acronym>
            <xocs:funding-agency>Natural Science Foundation of Zhejiang Province</xocs:funding-agency>
            <xocs:funding-agency-id>http://data.elsevier.com/vocabulary/SciValFunders/501100004731</xocs:funding-agency-id>
            <xocs:funding-agency-country>http://sws.geonames.org/1814991/</xocs:funding-agency-country>
         </xocs:funding>
         <xocs:funding-text>This work was supported by the National Natural Science Foundation of China ( 81830107 ) to Q.H., National Natural Science Foundation of China ( 81973349 ) to H.Z., and the Natural Science Foundation of Zhejiang Province (no. LR19H310002 ) to H.Z.</xocs:funding-text>
      </xocs:funding-list>
      <xocs:attachment-metadata-doc>
         <xocs:attachment-set-type>item</xocs:attachment-set-type>
         <xocs:pii-formatted>S1359-6446(20)30230-0</xocs:pii-formatted>
         <xocs:pii-unformatted>S1359644620302300</xocs:pii-unformatted>
         <xocs:eid>1-s2.0-S1359644620302300</xocs:eid>
         <xocs:doi>10.1016/j.drudis.2020.06.005</xocs:doi>
         <xocs:cid>271275</xocs:cid>
         <xocs:timestamp>2021-07-14T00:00:11.156898Z</xocs:timestamp>
         <xocs:cover-date-start>2020-08-01</xocs:cover-date-start>
         <xocs:cover-date-end>2020-08-31</xocs:cover-date-end>
         <xocs:attachments>
            <xocs:web-pdf>
               <xocs:attachment-eid>1-s2.0-S1359644620302300-main.pdf</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S1359644620302300/MAIN/application/pdf/21461f38324cdb622be4b72af3ba781c/main.pdf</xocs:ucs-locator>
               <xocs:filename>main.pdf</xocs:filename>
               <xocs:extension>pdf</xocs:extension>
               <xocs:pdf-optimized>true</xocs:pdf-optimized>
               <xocs:filesize>2165604</xocs:filesize>
               <xocs:web-pdf-purpose>MAIN</xocs:web-pdf-purpose>
               <xocs:web-pdf-page-count>11</xocs:web-pdf-page-count>
               <xocs:web-pdf-images>
                  <xocs:web-pdf-image>
                     <xocs:attachment-eid>1-s2.0-S1359644620302300-main_1.png</xocs:attachment-eid>
                     <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S1359644620302300/PREVIEW/image/png/559afc6c47fa0f990f65520fe1986b3a/main_1.png</xocs:ucs-locator>
                     <xocs:filename>main_1.png</xocs:filename>
                     <xocs:extension>png</xocs:extension>
                     <xocs:filesize>98425</xocs:filesize>
                     <xocs:pixel-height>849</xocs:pixel-height>
                     <xocs:pixel-width>656</xocs:pixel-width>
                     <xocs:attachment-type>IMAGE-WEB-PDF</xocs:attachment-type>
                     <xocs:pdf-page-num>1</xocs:pdf-page-num>
                  </xocs:web-pdf-image>
               </xocs:web-pdf-images>
            </xocs:web-pdf>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S1359644620302300-gr1.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S1359644620302300/gr1/DOWNSAMPLED/image/jpeg/a047a0eb97227a6bb1e883c808ee26d5/gr1.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr1</xocs:file-basename>
               <xocs:filename>gr1.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>90616</xocs:filesize>
               <xocs:pixel-height>430</xocs:pixel-height>
               <xocs:pixel-width>836</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S1359644620302300-gr2.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S1359644620302300/gr2/DOWNSAMPLED/image/jpeg/40b39eac7d8dd2459ad9d08cbed0c5a5/gr2.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr2</xocs:file-basename>
               <xocs:filename>gr2.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>82516</xocs:filesize>
               <xocs:pixel-height>471</xocs:pixel-height>
               <xocs:pixel-width>836</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S1359644620302300-gr3.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S1359644620302300/gr3/DOWNSAMPLED/image/jpeg/de4fd843c08d919d5cd844db4f846ad2/gr3.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr3</xocs:file-basename>
               <xocs:filename>gr3.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>122416</xocs:filesize>
               <xocs:pixel-height>567</xocs:pixel-height>
               <xocs:pixel-width>836</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S1359644620302300-gr4.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S1359644620302300/gr4/DOWNSAMPLED/image/jpeg/2c7ea826107e4351f7012d33cb1fc64a/gr4.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr4</xocs:file-basename>
               <xocs:filename>gr4.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>112050</xocs:filesize>
               <xocs:pixel-height>541</xocs:pixel-height>
               <xocs:pixel-width>836</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S1359644620302300-gr1.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S1359644620302300/gr1/THUMBNAIL/image/gif/d94faaf71e86e76838e85f4feda08211/gr1.sml</xocs:ucs-locator>
               <xocs:file-basename>gr1</xocs:file-basename>
               <xocs:filename>gr1.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>13659</xocs:filesize>
               <xocs:pixel-height>113</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S1359644620302300-gr2.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S1359644620302300/gr2/THUMBNAIL/image/gif/6a641fe2f5d9ba069867d0bde792a4e5/gr2.sml</xocs:ucs-locator>
               <xocs:file-basename>gr2</xocs:file-basename>
               <xocs:filename>gr2.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>15462</xocs:filesize>
               <xocs:pixel-height>123</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S1359644620302300-gr3.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S1359644620302300/gr3/THUMBNAIL/image/gif/db54d6871a2990f9dbb076a64bd0c004/gr3.sml</xocs:ucs-locator>
               <xocs:file-basename>gr3</xocs:file-basename>
               <xocs:filename>gr3.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>17970</xocs:filesize>
               <xocs:pixel-height>149</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S1359644620302300-gr4.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S1359644620302300/gr4/THUMBNAIL/image/gif/99ecc97106a95d4cc627f391fea0989b/gr4.sml</xocs:ucs-locator>
               <xocs:file-basename>gr4</xocs:file-basename>
               <xocs:filename>gr4.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>16582</xocs:filesize>
               <xocs:pixel-height>142</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S1359644620302300-gr1_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S1359644620302300/gr1/HIGHRES/image/jpeg/a4bc4dd7f37bc37b32d21f1e25ee0934/gr1_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr1</xocs:file-basename>
               <xocs:filename>gr1_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>755072</xocs:filesize>
               <xocs:pixel-height>1904</xocs:pixel-height>
               <xocs:pixel-width>3703</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S1359644620302300-gr2_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S1359644620302300/gr2/HIGHRES/image/jpeg/f9fe36ebc6a68d9bbb4d8706fc6fff85/gr2_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr2</xocs:file-basename>
               <xocs:filename>gr2_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>730252</xocs:filesize>
               <xocs:pixel-height>2088</xocs:pixel-height>
               <xocs:pixel-width>3703</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S1359644620302300-gr3_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S1359644620302300/gr3/HIGHRES/image/jpeg/d6cc25964c123cc6a0b8bc28bad04b57/gr3_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr3</xocs:file-basename>
               <xocs:filename>gr3_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>1090915</xocs:filesize>
               <xocs:pixel-height>2513</xocs:pixel-height>
               <xocs:pixel-width>3703</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S1359644620302300-gr4_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S1359644620302300/gr4/HIGHRES/image/jpeg/7716f16079519876ee04119cc0ca26e2/gr4_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr4</xocs:file-basename>
               <xocs:filename>gr4_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>943489</xocs:filesize>
               <xocs:pixel-height>2397</xocs:pixel-height>
               <xocs:pixel-width>3703</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S1359644620302300-am.pdf</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/egi:105G2PZRPN4/MAIN/application/pdf/a7768945d3a912b7da917f7048156b13/am.pdf</xocs:ucs-locator>
               <xocs:file-basename>am</xocs:file-basename>
               <xocs:filename>am.pdf</xocs:filename>
               <xocs:extension>pdf</xocs:extension>
               <xocs:pdf-optimized>false</xocs:pdf-optimized>
               <xocs:filesize>4337451</xocs:filesize>
               <xocs:attachment-type>AAM-PDF</xocs:attachment-type>
            </xocs:attachment>
         </xocs:attachments>
      </xocs:attachment-metadata-doc>
   </xocs:meta><xocs:serial-item xmlns:xoe="http://www.elsevier.com/xml/xoe/dtd">
      <article xmlns="http://www.elsevier.com/xml/ja/dtd" version="5.5" xml:lang="en" docsubtype="rev">
         <item-info>
            <jid>DRUDIS</jid>
            <aid>2705</aid>
            <ce:pii>S1359-6446(20)30230-0</ce:pii>
            <ce:doi>10.1016/j.drudis.2020.06.005</ce:doi>
            <ce:copyright type="full-transfer" year="2020">Elsevier Ltd</ce:copyright>
         </item-info>
         <ce:floats>
            <ce:figure id="fig0005">
               <ce:label>Figure 1</ce:label>
               <ce:caption id="cap0005">
                  <ce:simple-para id="spar0005" view="all">Approaches to modulating transcription factor (TF) stability by interfering with ubiquitination. (a) TF protection from degradation via disruption of E3 ligase binding. For TFs that act as tumour suppressors, targeting E3 ligase increase their protein levels to inhibit tumor progression. (b) Given that ubiquitination can be reversed by deubiquitinating enzymes (DUBs) specifically, DUB inhibitors lead to higher levels of ubiquitination and enhanced proteasomal degradation of TFs. (c) The mode of action of a proteolysis-targeting chimera (PROTAC). This technology uses a targeted protein-binding moiety (purple circle), a flexible chemical linker, and a ligand for recruiting degradation system (green square) to produce a heterobifunctional compound. Once the TF–PROTAC–E3 ubiquitin ligase complex is formed, E2-conjugating enzymes transfer ubiquitin (Ub) to cancer-causing TFs, leading to their degradation. (d) Small molecules target TFs directly to promote E3 ligase binding, leading to ubiquitination and proteasome-dependent destruction</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="at0005" role="short">Figure 1</ce:alt-text>
               <ce:link locator="gr1" xlink:href="pii:S1359644620302300/gr1" xlink:type="simple" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4"/></ce:link>
            </ce:figure>
            <ce:figure id="fig0010">
               <ce:label>Figure 2</ce:label>
               <ce:caption id="cap0010">
                  <ce:simple-para id="spar0010" view="all">The mode of action and unique features of proteolysis-targeting chimeras (PROTACs). (a) PROTAC component combinations. As a bi-functional molecule, the PROTAC contains a protein of interest (POI)-binding ligand, a linker, and a E3 ligase-binding moiety. POI-binding ligands show adequate affinity for the target proteins. The linkers are required to have appropriate physicochemical properties, thus polyethylene glycol (PEG) chains, alkane chains, and piperidine groups are commonly used. Well-known examples of E3-ligase binding moieties are MDM2, VHL, IAPs, and CRL4<ce:sup loc="post">CRBN</ce:sup>, which recruit the target proteins to E3 ubiquitin ligases and trigger their degradation. (b) An example of transcription factor (TF)-targeting PROTACs. Compound SD-36 comprises a STAT3 SH2 binder SI-109, an alkane linker, and a CRBN ligase. SD-36 artificially hijacks STAT3 to the CRL4<ce:sup loc="post">CRBN</ce:sup> complex, leading to its ubiquitination and proteasome-mediated degradation. For abbreviation definitions, please see the main text</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="at0010" role="short">Figure 2</ce:alt-text>
               <ce:link locator="gr2" xlink:href="pii:S1359644620302300/gr2" xlink:type="simple" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4"/></ce:link>
            </ce:figure>
            <ce:figure id="fig0015">
               <ce:label>Figure 3</ce:label>
               <ce:caption id="cap0015">
                  <ce:simple-para id="spar0015" view="all">Targeting transcription factors (TFs) by phosphorylation. (a) JAK2-mediated STAT3 phosphorylation and activation could be inhibited by compounds ECN and AZD1480. The SMAD signaling cascade is activated by TGF-βR to promote cancer cell metastasis, which can be abrogated by Nutlin-3. (b) A hypoxic microenvironment attenuates YAP phosphorylation and promotes YAP nucleus translocation mainly through HMGCR and IGF-1R. Statins, as HMGCR inhibitors, and the IGF1-R inhibitor CT-707 induce p-YAP with the loss of total protein abundance to overcome poor drug response under hypoxia. For abbreviation definitions, please see the main text</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="at0015" role="short">Figure 3</ce:alt-text>
               <ce:link locator="gr3" xlink:href="pii:S1359644620302300/gr3" xlink:type="simple" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4"/></ce:link>
            </ce:figure>
            <ce:figure id="fig0020">
               <ce:label>Figure 4</ce:label>
               <ce:caption id="cap0020">
                  <ce:simple-para id="spar0020" view="all">Modulating transcription factors (TFs) for cancer therapy by acetylation, methylation, and sumoylation. (a) p53 acetylation prevents its ubiquitination degradation. A novel SIRT inhibitor, MHY2256, significantly increases p53 acetylation. C646, a reversible p300 inhibitor, blocks overactivation of p53, and protects normal bone marrow cells from doxorubicin-induced toxicity. Moreover, C646 is reported to inhibit Snail acetylation and tumor malignancy. SAHA and MS27-275, two HDAC inhibitors, induce c-Myc acetylation, disrupting the binding of c-Myc and <ce:italic>TRAIL</ce:italic>. (b) FOXO1 is methylated by G9a, leading to colon cancer proliferation, which can be counteracted by BIX01294. (c) The therapeutic agent As<ce:inf loc="post">2</ce:inf>O<ce:inf loc="post">3</ce:inf> in APL treatment stimulates PML-dependent hypersumoylation, resulting in proteasomal degradation of PML-RARα to restore PML nuclear body integrity. (d) ML-792, a SAE inhibitor, is synthetic lethal with Myc overexpression; however, whether other proteins are involved is unknown. For abbreviation definitions, please see the main text</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="at0020" role="short">Figure 4</ce:alt-text>
               <ce:link locator="gr4" xlink:href="pii:S1359644620302300/gr4" xlink:type="simple" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4"/></ce:link>
            </ce:figure>
            <ce:table xmlns="http://www.elsevier.com/xml/common/cals/dtd" id="tbl0005" frame="topbot" rowsep="0" colsep="0">
               <ce:label>Table 1</ce:label>
               <ce:caption id="cap0025">
                  <ce:simple-para id="spar0025" view="all">TF PTMs as therapeutic targets<ce:sup loc="post">a</ce:sup>
                  </ce:simple-para>
               </ce:caption>
               <ce:alt-text id="at0025" role="short">Table 1</ce:alt-text>
               <tgroup cols="8">
                  <colspec colname="col1"/></colspec>
                  <colspec colname="col2"/></colspec>
                  <colspec colname="col3"/></colspec>
                  <colspec colname="col4"/></colspec>
                  <colspec colname="col5"/></colspec>
                  <colspec colname="col6"/></colspec>
                  <colspec colname="col7"/></colspec>
                  <colspec colname="col8"/></colspec>
                  <thead valign="top">
                     <row rowsep="1">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">PTMs</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Mode of actions</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Agent</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Primary target</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Regulated TF</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Potential therapeutic activity</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Research stage</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Refs</entry>
                     </row>
                  </thead>
                  <tbody>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left" valign="middle" morerows="14" role="rowhead rowgroup">Ubiquitination</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left" valign="middle" morerows="5" role="rowhead">E3 ligase modulation</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">SP-141</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">MDM2</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">p53</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Exerts therapeutic effects in breast cancer cells with IC<inf loc="post">50</inf> <1<hsp sp="0.25"/></hsp>μM</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Preclinical</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <cross-refs id="crfs0005" refid="bib0045 bib0050">[9,10]</cross-refs>
                        </entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left" role="rowhead">Nutlin-3a</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">MDM2</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">p53</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Exerts therapeutic effects in breast cancer and nasopharyngeal carcinoma</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Preclinical</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <cross-refs id="crfs0010" refid="bib0045 bib0050">[9,10]</cross-refs>
                        </entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left" role="rowhead">RG7112</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">MDM2</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">p53</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Exhibits clinical activity against relapsed AML and CLL at 20–1920<hsp sp="0.25"/></hsp>mg/m<sup loc="post">2</sup> orally once-daily</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Phase I in hematologic neoplasms (completed): NCT00623870; Phase I in advanced solid cancers (completed): NCT00559533</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <cross-ref id="crf0005" refid="bib0055">[11]</cross-ref>
                        </entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left" role="rowhead">AMG232</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">MDM2</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">p53</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Shows sensitivity in four patient-derived glioblastoma cells with average IC<inf loc="post">50</inf> 0.076<hsp sp="0.25"/></hsp>μM</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Phase I in brain cancer (recruiting): NCT03107780; Phase Ib/IIa in metastatic melanoma (completed): NCT02110355; Phase I in solid tumors or MM (completed): NCT01723020</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <cross-ref id="crf0010" refid="bib0060">[12]</cross-ref>
                        </entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left" role="rowhead">NVP-CGM097</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">MDM2</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">p53</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Shows additive antiproliferative effects in neuroendocrine tumor cells with 5-FU, TMZ, or everolimus at 2.5 μM</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Phase I advanced solid tumors (active): NCT01760525</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <cross-ref id="crf0015" refid="bib0065">[13]</cross-ref>
                        </entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left" role="rowhead">HLI373</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">MDM2</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">RARα</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Synergizes with ATRA in the differentiation treatment at 5 μM</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Preclinical</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <cross-ref id="crf0020" refid="bib0070">[14]</cross-ref>
                        </entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left" valign="middle" morerows="4" role="rowhead rowgroup">DUB inhibition</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left" role="rowhead">SJB3−019A</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">USP1</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">SOX-2/4</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Downregulates Notch-1/2 and SOX-2/4 to inhibit MM aggression with IC<inf loc="post">50</inf> 0.1–0.5 μM</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Preclinical</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <cross-ref id="crf0025" refid="bib0080">[16]</cross-ref>
                        </entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left" role="rowhead">Pimozide</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">USP1</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">ID1</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Destabilizes ID1 and CHEK1 to inhibit GSCs with concentration less than 10<hsp sp="0.25"/></hsp>μM</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Phase II in amyotrophic lateral sclerosis: NCT03272503</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <cross-ref id="crf0030" refid="bib0085">[17]</cross-ref>
                        </entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left" role="rowhead">P0217564</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">USP7</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">FOXP3</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Enhances efficacy of antitumor vaccines of anti-PD1 at 1<hsp sp="0.25"/></hsp>mg/kg/day in mice bearing TC1 lung tumors</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Preclinical</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <cross-ref id="crf0035" refid="bib0090">[18]</cross-ref>
                        </entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left" role="rowhead">WP-1130</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">USP and UCH</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">PBX1</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Degrades PBX1 in prostate cancer cells at <10<hsp sp="0.25"/></hsp>μM</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Preclinical</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <cross-ref id="crf0040" refid="bib0095">[19]</cross-ref>
                        </entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left" role="rowhead">Spautin-1</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">USP10</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Smad4</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Attenuates Smad4-mediated HCC migration at <10<hsp sp="0.25"/></hsp>μM</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Preclinical</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <cross-ref id="crf0045" refid="bib0100">[20]</cross-ref>
                        </entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left" valign="middle" morerows="2" role="rowhead rowgroup">PROTACs</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left" role="rowhead">ARV-110</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">AR</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">AR</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Shows activity in AR mutation and overexpression mouse models at 10 mpk PO QD dose</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Phase I in metastatic castration- resistant prostate cancer (recruiting): NCT03888612</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <cross-ref id="crf0050" refid="bib0125">[25]</cross-ref>
                        </entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left" role="rowhead">ARV-471</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">ER</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">ER</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Exerts superior tumor growth inhibition in ER<sup loc="post">+</sup>/HER2– breast cancer mouse model at 10 mpk PO QD dose</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Phase I in ER<sup loc="post">+</sup>/HER2– locally advanced or metastatic breast cancer (recruiting): NCT04072952</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <cross-ref id="crf0055" refid="bib0130">[26]</cross-ref>
                        </entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left" role="rowhead">SD-36</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">STAT3</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">STAT3</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Shows strong suppression in AML and ALCL mouse models at 25 and 50<hsp sp="0.25"/></hsp>mg/kg weekly dosing for 4 weeks</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Preclinical</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <cross-ref id="crf0060" refid="bib0140">[28]</cross-ref>
                        </entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left" role="rowhead">Promoting proteolysis by small molecules binding to TFs</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Thalidomide and its analogs</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Some C2H2 ZF TFs</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Some C2H2 ZF TFs</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Mediates CRL4<sup loc="post">CRBN</sup>-dependent degradation of a larger number of C2H2 ZF proteins</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Phase IV in NSCLC combined with conmana: NCT02778893; Phase IV in second-line advanced gastric cancer combined with Irinotecan: NCT02401971; Phase IV in MM with bortezomib (completed): NCT00652041</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <cross-refs id="crfs0015" refid="bib0155 bib0160">[31,32]</cross-refs>
                        </entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left" valign="middle" morerows="7" role="rowhead rowgroup">Phosphorylation</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left" valign="middle" morerows="4" role="rowhead">Phosphokinases or TGF-β inhibition</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">ECN</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">JAK-STAT axis</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">STAT3</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Shows potent cytotoxic effects against MDA-MB-231 with IC<inf loc="post">50</inf> ∼6.85 μM</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Preclinical</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <cross-ref id="crf0065" refid="bib0180">[36]</cross-ref>
                        </entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left" role="rowhead">AZD1480</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">JAK</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">STAT3</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Shows enhanced effects with gemcitabine in PKT mice at 20<hsp sp="0.25"/></hsp>mg/kg twice a week</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Phase I in solid malignancies (terminated): NCT01112397</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <cross-ref id="crf0070" refid="bib0185">[37]</cross-ref>
                        </entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left" role="rowhead">Dasatinib</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Src kinase</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">ETS1</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Decreases ETS1 abundance in MDA-MB-231 cells at 10<hsp sp="0.25"/></hsp>μM</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Phase IV in CML (completed): NCT01660906</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <cross-ref id="crf0075" refid="bib0195">[39]</cross-ref>
                        </entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left" role="rowhead">MK2206</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">AKT</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">ZNF322A</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Attenuates phosphorylation of ZNF322A at 2.5 μM</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Phase II in advanced NSCLC (active): NCT01248247</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <cross-ref id="crf0080" refid="bib0200">[40]</cross-ref>
                        </entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left" role="rowhead">Nutlin-3</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">TGF-β1-SMAD axis</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Smad2/3</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Sensitizes anticancer activities of EGFR inhibitors at 5 μM</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Preclinical</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <cross-ref id="crf0085" refid="bib0205">[41]</cross-ref>
                        </entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left" valign="middle" morerows="2" role="rowhead rowgroup">Promoting phosphorylation</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left" role="rowhead">Statins</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">HMGCR</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">YAP</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Counteracts hypoxia-mediated sorafenib and irinotecan resistance at <10<hsp sp="0.25"/></hsp>μM in HCC</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Phase II in SCLC combined with irinotecan (completed): NCT00452634; Phase II in metastatic colorectal cancer with irinotecan (completed): NCT01281761</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <cross-ref id="crf0090" refid="bib0220">[44]</cross-ref>
                        </entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left" role="rowhead">CT-707</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">IGF1R-YAP axis</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">YAP</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Interrupts IGF1R-YAP axis in HCC with IGF1R kinase activity IC<inf loc="post">50</inf> value of 0.011<hsp sp="0.25"/></hsp>μM</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Phase I in ALK-positive NSCLC: NCT02695550</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <cross-ref id="crf0095" refid="bib0225">[45]</cross-ref>
                        </entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left" role="rowhead">Compounds 361 and 975</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Unknown</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Myc</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Potentiates anti-PD1 immunotherapy at 100<hsp sp="0.25"/></hsp>mg/kg/day in MycCaP allografts</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Preclinical</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <cross-ref id="crf0100" refid="bib0235">[47]</cross-ref>
                        </entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left" valign="middle" morerows="3" role="rowhead rowgroup">Acetylation</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left" role="rowhead">Acetyltransferase inhibition</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">C646</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">CBP</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">p53/ snail</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Protects normal bone marrow cells from doxorubicin-induced toxicity at 1<hsp sp="0.25"/></hsp>μM; remodels tumor microenvironment through Snail at 6<hsp sp="0.25"/></hsp>μM</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Preclinical</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <cross-refs id="crfs0020" refid="bib0265 bib0270">[53,54]</cross-refs>
                        </entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left" valign="middle" morerows="2" role="rowhead rowgroup">Deacetylases inhibition</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left" role="rowhead">MHY2256</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">SIRT</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">p53</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Induces apoptosis in endometrial cancer cells at concentrations <50 μM</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Preclinical</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <cross-ref id="crf0105" refid="bib0260">[52]</cross-ref>
                        </entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left" role="rowhead">SAHA</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">HDAC</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">c-Myc</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Reveals anticancer effects in AML blasts and primary human breast cancer cells at 5 μM</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Phase II in relapsed/refractory AML combined with temozolomide (completed): NCT01550224; Phase II in breast cancer combined with tamoxifen (completed): NCT00365599</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <cross-ref id="crf0110" refid="bib0275">[55]</cross-ref>
                        </entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left" role="rowhead">MS27−275</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">HDAC</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">c-Myc</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Reveals anticancer effects in AML blasts and primary human breast cancer cells at 5 μM</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Phase I in AML combined with 5AC (recruiting): NCT01305499; Phase III in advanced breast cancer with exemestane (recruiting): NCT03538171</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <cross-ref id="crf0115" refid="bib0275">[55]</cross-ref>
                        </entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" role="rowhead" align="left">Methylation</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Methyltransferase inhibition</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">BIX01294</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">G9a</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">FOXO1</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Counteracts colon cancer cell proliferation at 1<hsp sp="0.25"/></hsp>μM</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Preclinical</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <cross-ref id="crf0120" refid="bib0305">[61]</cross-ref>
                        </entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left" valign="middle" morerows="1" role="rowhead rowgroup">Sumoylation</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left" role="rowhead">Sumoylation stimulation</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">As<inf loc="post">2</inf>O<inf loc="post">3</inf>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">PML-RARα</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">PML-RARα</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Stimulates hypersumoylation at 1<hsp sp="0.25"/></hsp>μM to restore PML nuclear body integrity in APL treatment</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Phase IV in APL combined with ATRA (active, not recruiting): NCT01987297</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <cross-ref id="crf0125" refid="bib0320">[64]</cross-ref>
                        </entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left" role="rowhead">E1 ligase inhibition</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">ML-792</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">SAE1/2</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Myc (might not be limited to this TF)</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Shows synthetically lethal with Myc overexpression in SK-MEL-28 cells at concentration <10<hsp sp="0.25"/></hsp>μM</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Preclinical</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <cross-ref id="crf0130" refid="bib0330">[66]</cross-ref>
                        </entry>
                     </row>
                  </tbody>
               </tgroup>
               <ce:legend>
                  <ce:simple-para id="spar0030" view="all">
                     <ce:sup loc="post">a</ce:sup>Abbreviations: ALK, anaplastic lymphoma kinase; EGFR, epidermal growth factor receptor; HER2, human epidermal growth factor receptor 2; NSCLC, nonsmall cell lung cancer; PO, per oral; QD, once daily; SAHA, vorinostat.</ce:simple-para>
               </ce:legend>
            </ce:table>
         </ce:floats>
         <head>
            <ce:dochead id="doh0005">
               <ce:textfn>Review</ce:textfn>
               <ce:dochead id="doh0010">
                  <ce:textfn>Post screen</ce:textfn>
               </ce:dochead>
            </ce:dochead>
            <ce:title id="tit0005">Targeting post-translational modification of transcription factors as cancer therapy</ce:title>
            <ce:author-group id="aug0005">
               <ce:author id="aut0005" author-id="S1359644620302300-13e6385b2f7a0c9298e4b08447bb95cd">
                  <ce:given-name>Meijia</ce:given-name>
                  <ce:surname>Qian</ce:surname>
               </ce:author>
               <ce:author id="aut0010" author-id="S1359644620302300-ac6e0ff0e63e8db572658038d560cdeb">
                  <ce:given-name>Fangjie</ce:given-name>
                  <ce:surname>Yan</ce:surname>
               </ce:author>
               <ce:author id="aut0015" author-id="S1359644620302300-6cb695ee0a4f0c57de941fee83c6b6dd">
                  <ce:given-name>Tao</ce:given-name>
                  <ce:surname>Yuan</ce:surname>
               </ce:author>
               <ce:author id="aut0020" author-id="S1359644620302300-2380641026498348a3e5aa6cab951540">
                  <ce:given-name>Bo</ce:given-name>
                  <ce:surname>Yang</ce:surname>
               </ce:author>
               <ce:author id="aut0025" author-id="S1359644620302300-2bde9236d072224d30ea69426ece26be">
                  <ce:given-name>Qiaojun</ce:given-name>
                  <ce:surname>He</ce:surname>
                  <ce:cross-ref id="crf0135" refid="cor0005">⁎</ce:cross-ref>
                  
               </ce:author>
               <ce:author id="aut0030" orcid="0000-0002-2575-4031" author-id="S1359644620302300-d5631831f47e8e9a4bcb816a8d5bc0aa">
                  <ce:given-name>Hong</ce:given-name>
                  <ce:surname>Zhu</ce:surname>
                  <ce:cross-ref id="crf0140" refid="cor0005">⁎</ce:cross-ref>
                  
               </ce:author>
               <ce:affiliation id="aff0005" affiliation-id="S1359644620302300-0c56895cc0b594a27f3c56e682aaea52">
                  <ce:textfn>Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, China</ce:textfn>
                  <sa:affiliation>
                     <sa:organization>Zhejiang Province Key Laboratory of Anti-Cancer Drug Research</sa:organization>
                     <sa:organization>College of Pharmaceutical Sciences</sa:organization>
                     <sa:organization>Zhejiang University</sa:organization>
                     <sa:city>Hangzhou</sa:city>
                     <sa:country>China</sa:country>
                  </sa:affiliation>
               </ce:affiliation>
               <ce:correspondence id="cor0005">
                  <ce:label>⁎</ce:label>
                  <ce:text>
                     <ce:italic>Corresponding authors</ce:italic>:</ce:text>
               </ce:correspondence>
            </ce:author-group>
            
            <ce:abstract id="abs0010" view="all" class="author"><ce:abstract-sec id="abst0010" view="all">
                  <ce:simple-para id="spar0040" view="all">Dysregulated transcription factors (TFs) fuel aberrant gene expression networks, resulting in cell overproliferation, migration, and immunosuppression. Given that TFs are regarded to have vital roles in tumors, various approaches are exploited to modulate their activities. Nevertheless, except for some ligand-binding nuclear receptors, most TFs are still considered ‘undruggable’ targets. Responding to extra- or intracellular stimuli, TFs are decorated with an array of post-translational modifications (PTMs) to regulate their subcellular localizations, protein–protein/DNA interactions, and stability. These PTMs orchestrate the multiple functions of TFs, thus offering numerous potential targets. In this review, we systematically review emerging concepts and effective agents in PTMs-associated TF-targeting, which could provide paradigms for cancer treatment.</ce:simple-para>
               </ce:abstract-sec></ce:abstract>
         </head>
         <body view="all">
            <ce:sections>
               <ce:section id="sec0005" role="introduction" view="all">
                  <ce:section-title id="sect0010">Introduction</ce:section-title>
                  <ce:para id="par0025" view="all">TFs are essential components that control gene expression networks to respond to extra- or intracellular stimuli and determine the destiny of cells. Research has validated numerous TFs as drivers and the ‘Achilles’ Heel’ of various tumors <ce:cross-refs id="crfs0025" refid="bib0005 bib0010">[1,2]</ce:cross-refs>. For example, recent studies highlighted the link between promyelocytic leukaemia (PML) protein-retinoic acid receptor α (RARα) and acute myeloid leukaemia (AML) <ce:cross-ref id="crf0145" refid="bib0005">[1]</ce:cross-ref>. With the increasing number of TFs being highlighted as anticancer targets, numerous approaches are being exploited to modulate TF activities. However, except for ligand-inducible nuclear receptors [mainly the RAR, glucocorticoid (GR), estrogen (ER), and androgen (AR) receptors], most TFs are still considered ‘undruggable’ targets because of their intractable active pockets <ce:cross-refs id="crfs0030" refid="bib0005 bib0015">[1,3]</ce:cross-refs>. Moreover, the challenges associated with targeting either protein–protein or protein–DNA interactions further result in a paucity of active compounds <ce:cross-refs id="crfs0035" refid="bib0005 bib0015">[1,3]</ce:cross-refs>. Therefore, alternative strategies need to be explored to target TF-associated cancers.</ce:para>
                  <ce:para id="par0030" view="all">Accumulating evidence reveals the crucial regulatory roles of PTMs on TFs. Although TFs comprise only ∼7% of the human proteome, PTMs endow them with incredible versatility, from various subcellular localizations and protein stabilities to protein–protein interactions and sequence-specific DNA binding <ce:cross-ref id="crf0150" refid="bib0020">[4]</ce:cross-ref>. Among the well-studied PTMs of TFs are ubiquitination, phosphorylation, acetylation, methylation, and sumoylation. Compared with other proteins, TFs generally harbor a lower level of ubiquitination, whereas sumoylation on TFs is significantly increased. For other PTMs, such as phosphorylation, acetylation, and methylation, their enrichment levels on TFs are approximately the same as on other proteins, according to the PhosphoSitePlus database <ce:cross-ref id="crf0155" refid="bib0020">[4]</ce:cross-ref>. In addition, these PTMs not only occur individually, but also interconnect with each other. Therefore, targeting one PTM could lead to a cascade of changes in gene transcription networks, thus imposing extensive and potent regulation of cellular signaling. Easily detected, the ubiquitination and phosphorylation of TFs are particularly well studied.</ce:para>
                  <ce:para id="par0035" view="all">Given the importance of PTMs in dictating multiple patterns of TFs, it is not surprising that the many PTMs of TFs have offered abundant potential targets for developing therapeutic agents against cancer (<ce:cross-ref id="crf0160" refid="tbl0005">Table 1</ce:cross-ref>
                     <ce:float-anchor refid="tbl0005"/></ce:float-anchor>), such as the recent success in proteolysis-targeting chimera (PROTAC), such as ARV-110 and ARV-471 (Arvinas, Inc.). Other agents, such as Nutlin-3a, thalidomide, and statins. also show promise. Here, we review emerging concepts and technical advances in PTM-associated TF targeting that could provide paradigms in cancer treatment.</ce:para>
               </ce:section>
               <ce:section id="sec0010" view="all">
                  <ce:section-title id="sect0015">Targeting TF ubiquitination</ce:section-title>
                  <ce:para id="par0040" view="all">Ubiquitination is a conserved cascade reaction to maintain protein homeostasis that begins with the activation of E1 ubiquitin-activating enzyme, the transfer of ubiquitin (Ub) to E2 Ub-conjugating enzyme, followed by the formation of an isopeptide bond between Ub and the substrate by E3 ubiquitin ligase. Ub has seven lysine residues (K6, K11, K27, K29, K33, K48, and K63) that can be polymerized into various topologies to dictate the fate of substrates. Of note, K11- and K48-linked Ub-chains form a ‘closed’ conformation and lead to 26S proteasome-catalyzed degradation, whereas K63 forms an ‘open’ conformation to alter the function of substrates <ce:cross-refs id="crfs0040" refid="bib0025 bib0030 bib0035">[5–7]</ce:cross-refs>. Mounting evidence reveals that TF ubiquitination is deregulated in human cancers, and both proteolytic and nonproteolytic mechanisms are involved.</ce:para>
                  <ce:section id="sec0015" view="all">
                     <ce:section-title id="sect0020">Interfering with TF ubiquitination for proteolytic regulation</ce:section-title>
                     <ce:para id="par0045" view="all">Targeting proteins for degradation through the fusion of precision chemistry and powerful cellular enzymatic machinery has emerged as a possible small-molecule therapeutic approach. Compounds canonically called degraders catalyze the specific ubiquitination of targets mainly by hijacking E3 ligases and deubiquitinating enzymes. Given that mounting evidence reveals that the proteolytic regulation of TFs is dysregulated in human cancers, targeting TF ubiquitination for proteolytic regulation has become an attractive idea (<ce:cross-ref id="crf0165" refid="fig0005">Fig. 1</ce:cross-ref>
                        <ce:float-anchor refid="fig0005"/></ce:float-anchor>).</ce:para>
                     <ce:section id="sec0020" view="all">
                        <ce:section-title id="sect0025">Modulating proteasome degradation through E3 ligase</ce:section-title>
                        <ce:para id="par0050" view="all">Many studies have shown that the aberrant expression or mutation of E3 ligases are closely associated with human cancers because the abundance of a variety of important TFs is tightly regulated by E3 ligases <ce:cross-refs id="crfs0045" refid="bib0040 bib0045">[8,9]</ce:cross-refs>.</ce:para>
                        <ce:para id="par0055" view="all">Among these TFs, p53 stands out because of its crucial tumor-suppressive roles. In most human cancers, the expression of p53 is deficient, owing to the high level of its E3 ubiquitin ligase murine double minute 2 (MDM2). MDM2-mediated p53 ubiquitination and degradation promote cancer malignancy and, thus, are an attractive target for the treatment of cancers displaying a low level of p53 and high level of MDM2 <ce:cross-ref id="crf0170" refid="bib0045">[9]</ce:cross-ref>. The specific MDM2 inhibitors SP-141 and Nutlin-3a disrupt the occupation of the hydrophobic pocket of p53, exerting potent therapeutic effects in breast cancer and nasopharyngeal carcinoma <ce:cross-refs id="crfs0050" refid="bib0045 bib0050">[9,10]</ce:cross-refs>. In addition, RG7112, a Nutlin-3a derivative, exhibits clinical activity against relapsed AML and chronic lymphocytic leukemia (CLL). The most frequently reported adverse events are neutropenia (30 %) and thrombocytopenia (15 %) <ce:cross-ref id="crf0175" refid="bib0055">[11]</ce:cross-ref>. Compound AMG232 shows more sensitive than RG7112 in four patient-derived glioblastoma cells <ce:cross-ref id="crf0180" refid="bib0060">[12]</ce:cross-ref>. Novel MDM2 inhibitors, such as NVP-CGM097, show additive antiproliferative effects in neuroendocrine tumor cells with 5-fluorouracil (5-FU), temozolomide (TMZ), or everolimus <ce:cross-ref id="crf0185" refid="bib0065">[13]</ce:cross-ref>. As well as p53, MDM2 also modulates the stability of RARα, which works as a heterodimer with retinoid X receptor (RXR) in all-<ce:italic>trans</ce:italic> retinoic acid (ATRA)-induced differentiation therapy. The therapeutic activity of ATRA is weakened by the degradation of RARα through the MDM2-mediated ubiquitin proteasome pathway <ce:cross-ref id="crf0190" refid="bib0070">[14]</ce:cross-ref>. Ying et al. reported that the MDM2 inhibitor HLI373 synergizes with ATRA, showing enhanced differentiation of osteosarcoma cells <ce:cross-ref id="crf0195" refid="bib0070">[14]</ce:cross-ref>.</ce:para>
                        <ce:para id="par0060" view="all">Thus, MDM2-regulated TFs are excellent examples of E3 ligase-mediated tumor therapy. Although the development of E3 ligase inhibitors has proven challenging because of the large contact surfaces between E3 and TFs, their high substrate specificity, and fewer off-target effects support their clinical application.</ce:para>
                     </ce:section>
                     <ce:section id="sec0025" view="all">
                        <ce:section-title id="sect0030">Destabilization of TFs by inhibiting DUBs</ce:section-title>
                        <ce:para id="par0065" view="all">Given that ubiquitination can be reversed by deubiquitinating enzymes (DUBs), DUB regulators are also regarded as crucial targets for TF-based pharmaceutical treatment. As a result of the exquisite sensitivity of multiple myeloma (MM) to proteasome inhibitors, pharmacological intervention of ubiquitination in myeloma has received much attention <ce:cross-ref id="crf0200" refid="bib0075">[15]</ce:cross-ref>. For example, by utilizing the Ub-specific protease 1 (USP1) inhibitor SJB3−019A in myeloma cell lines, Das et al. found that SJB3−019A not only triggers apoptosis via activation of caspase cascades, but also downregulates surface receptor Notch-1/2 and TF SOX-2/4 to inhibit tumor aggression <ce:cross-ref id="crf0205" refid="bib0080">[16]</ce:cross-ref>. Lee et al. also reported that the USP1 inhibitor pimozide destabilizes the TF inhibitor of DNA binding 1 (ID1) and checkpoint kinase 1 (CHEK1), attenuating clonogenic growth and survival of glioblastoma stem-like cells (GSCs) <ce:cross-ref id="crf0210" refid="bib0085">[17]</ce:cross-ref>. USP7 is reported to stabilize forkhead box P3 (FOXP3), a crucial TF determining the differentiation of regulatory T cells (Tregs). Given that Tregs are known to suppress immune responses, Wang et al. reported that pharmacological inhibition of USP7 via compound P0217564 can limit tumor growth in immunocompetent mice and enhance the efficacy of antitumor vaccines of anti-PD1 <ce:cross-ref id="crf0215" refid="bib0090">[18]</ce:cross-ref>. WP-1130 is a well-used compound that inhibits several DUBs of USP and ubiquitin C-terminal hydrolase (UCH) subclasses. It rapidly induces K48-linked polyubiquitination and degradation of oncogenic TF pre-B cell leukaemia homeobox-1 (PBX1) protein by inhibiting its DUB USP9X <ce:cross-ref id="crf0220" refid="bib0095">[19]</ce:cross-ref>. Recent research also found that the suppression of USP10 by Spautin-1 significantly inhibits its substrate Smad4-mediated hepatocellular carcinoma (HCC) migration <ce:cross-ref id="crf0225" refid="bib0100">[20]</ce:cross-ref>.</ce:para>
                        <ce:para id="par0070" view="all">During the past few decades, many studies have implicated DUBs in tumor immunity, cell cycle progression, and signal transduction. Thus, they are proposed as alternative targets that may generate more specific and less toxic anticancer agents <ce:cross-ref id="crf0230" refid="bib0090">[18]</ce:cross-ref>. Thus, with dramatic advances in DUBs for some key TFs/cofactors, such as Yes-associated protein (YAP)/transcriptional coactivator with PDZ-binding motif (TAZ), Myc, and NF-κB, and improvements in DUB screening technologies and biochemical assays, it is possible to find candidate compounds <ce:cross-ref id="crf0235" refid="bib0105">[21]</ce:cross-ref>.</ce:para>
                     </ce:section>
                     <ce:section id="sec0030" view="all">
                        <ce:section-title id="sect0035">PROTAC</ce:section-title>
                        <ce:para id="par0075" view="all">To avoid tractable active sites, a new technology, PROTAC, was developed to trigger ubiquitination and subsequent degradation. This technology uses a targeted protein-binding moiety, a flexible chemical linker, and a ligand for recruiting the degradation system (mainly MDM2, VHL, IAPs, and CRL4<ce:sup loc="post">CRBN</ce:sup>) to produce a heterobifunctional compound (<ce:cross-ref id="crf0240" refid="fig0010">Fig. 2</ce:cross-ref>
                           <ce:float-anchor refid="fig0010"/></ce:float-anchor>A) <ce:cross-refs id="crfs0055" refid="bib0110 bib0115">[22,23]</ce:cross-refs>. One of the most typical examples is the bromodomain and extra-terminal (BET) PROTAC, including ARV-825 and ARV-771 (Arvinas, Inc.) <ce:cross-ref id="crf0245" refid="bib0120">[24]</ce:cross-ref>.</ce:para>
                        <ce:para id="par0080" view="all">Recently, Arvinas demonstrated this approach for TF targeting with two orally bioavailable PROTACs, ARV-110 and ARV-471, degrading nuclear receptor AR and ER, respectively. ARV-110 shows high activity in AR mutation or overexpression preclinical models, with an observed half-maximal degradation concentration of <1<ce:hsp sp="0.25"/></ce:hsp>nM. In an enzalutamide-resistant prostate PDX mouse model, ARV-110 significantly inhibited tumor growth at a 10 mpk PO QD dose. It might also overcome the resistance that frequently occurs with currently available AR-targeted therapies. This agent is currently being evaluated in a Phase I clinical trial and has been granted Fast Track designation by the US Food and Drug Administration (FDA) for the treatment of metastatic castration-resistant prostate cancer <ce:cross-ref id="crf0250" refid="bib0125">[25]</ce:cross-ref>. ARV-471 is catalytically active at a 10 mpk PO QD dose, exerting superior tumor growth inhibition compared with fulvestrant in a patient-derived xenograft (PDX) model from patient with mutated ESR1. Arvinas is evaluating ARV-471 in a Phase I clinical trial with ER-positive and HER2-negative breast cancer <ce:cross-ref id="crf0255" refid="bib0130">[26]</ce:cross-ref>. As Ciulli said, ‘Buoyed by fresh targets and clinical trials about to begin, researchers are ready to prove that protein degraders can be more than a parlour trick.’ <ce:cross-ref id="crf0260" refid="bib0135">[27]</ce:cross-ref>.</ce:para>
                        <ce:para id="par0085" view="all">Another prominent example is SD-36, a newly reported selective degrader of signal transducer and activator of transcription 3 (STAT3), comprising a Src homology 2 (SH2) domain inhibitor SI-109, a linker, and lenalidomide (<ce:cross-ref id="crf0265" refid="fig0010">Fig. 2</ce:cross-ref>B) <ce:cross-ref id="crf0270" refid="bib0140">[28]</ce:cross-ref>. Given that STAT3 can be persistently activated to regulate cancerous cell proliferation, pluripotency, and immune escape but is dispensable for normal cells, it is deemed to be a valid target <ce:cross-ref id="crf0275" refid="bib0145">[29]</ce:cross-ref>. Bai et al. demonstrated that SD-36 degrades STAT3, leading to intense transcriptional network inhibition in AML and anaplastic large cell lymphoma (ALCL) cells. In addition, with good bioavailability, SD-36 achieved complete and lasting tumor regression in MOLM-16, SU-DHL-1 and SUP-M2 xenograft mouse models <ce:cross-ref id="crf0280" refid="bib0140">[28]</ce:cross-ref>.</ce:para>
                        <ce:para id="par0090" view="all">Different from traditional small-molecule inhibitors, PROTACs are expected to hijack Ub-proteasome to destroy cancer-causing TFs, which might provide a better and more efficient strategy. However, the slow development of highly specific small molecules and high-efficient linkers impact the current therapeutic application of PROTACs. Moreover, suitable E3 ligases also need ti be identified.</ce:para>
                     </ce:section>
                     <ce:section id="sec0035" view="all">
                        <ce:section-title id="sect0040">Promoting proteolysis by small-molecule binding to TFs</ce:section-title>
                        <ce:para id="par0095" view="all">One of the best approaches to interfere with TF activity with small molecules is to directly target TFs for proteolysis, among which nuclear receptor-targeting strategies, such as ATRA (which binds to PML-RARɑ), have achieved remarkable clinical efficacy <ce:cross-ref id="crf0285" refid="bib0150">[30]</ce:cross-ref>.</ce:para>
                        <ce:para id="par0100" view="all">Recent studies found that several of the above-mentioned E3 ‘ligands’ (thalidomide, lenalidomide, and pomalidomide) can result in selective ubiquitination and degradation of two lymphoid TFs, IKZF1 and IKZF3, through the CRL4<ce:sup loc="post">CRBN</ce:sup> Ub ligase <ce:cross-refs id="crfs0060" refid="bib0155 bib0160">[31,32]</ce:cross-refs>. Despite their history as human teratogens, these agents have been clinically approved to treat MM and other hematological malignancies. This opens doors for TF-targeted cancer therapeutic regimens because this mechanism of action might contribute to their superior clinical efficacy. Dimopoulos et al. illustrated the safety and efficacy of pomalidomide (4<ce:hsp sp="0.25"/></ce:hsp>mg on days 1–21 of 28-day cycles) plus low-dose dexamethasone (40<ce:hsp sp="0.25"/></ce:hsp>mg on days 1, 8, 15, and 22) against refractory MM. It ws reported that the toxicities are manageable, mostly comprising neutropenia (49.7 %) and anemia (33.0 %) <ce:cross-ref id="crf0290" refid="bib0165">[33]</ce:cross-ref>. Thomä et al. further screened the zinc finger (ZF) library and showed that thalidomide and its analogs degrade numerous C2H2 ZF proteins in a CRL4<ce:sup loc="post">CRBN</ce:sup>-dependent mechanism <ce:cross-ref id="crf0295" refid="bib0160">[32]</ce:cross-ref>. Different ZF degrons can bind to the same complementary groove on the drug-CRL4<ce:sup loc="post">CRBN</ce:sup> surface because of the shift of overall shape. Thus, other than the primitive interactions of ZF and CRL4<ce:sup loc="post">CRBN</ce:sup> side chains, the direct bond between thalidomide analogs and ZF residues might contribute to the high efficiency and specificity of TF degradation. For example, IKZF2/4 ZF2 is not impacted by pomalidomide and lenalidomide but is degraded by the thalidomide analog CC-220 in a unique crystal structure <ce:cross-ref id="crf0300" refid="bib0160">[32]</ce:cross-ref>. Therefore, with modified chemical scaffolds, thalidomide analogs may allow the selective degradation of distinct C2H2 ZF TFs.</ce:para>
                     </ce:section>
                  </ce:section>
                  <ce:section id="sec0040" view="all">
                     <ce:section-title id="sect0045">Interfering with nonproteolytic ubiquitination of TFs</ce:section-title>
                     <ce:para id="par0105" view="all">As mentioned above, K48- and K11-linked ubiquitin chains are generally signals for proteasomal degradation, whereas K63-linked ubiquitin chains more often generate signals for activation and subcellular localization modification. For example, several pieces of evidence suggest that cIAP1-mediated K63 ubiquitination of E2F1 on the lysine residues 161 and 164 is a signal for the activation of E2F1 during early S phase or in response to DNA damage <ce:cross-ref id="crf0305" refid="bib0170">[34]</ce:cross-ref>. In addition, YAP is a transcriptional co-activator in regulating tumorigenesis, which must shuttle from cytoplasm to the nucleus to interact with TEA domain (TEAD) family members. Yao <ce:italic>et al.</ce:italic> demonstrated that, in the homeostasis of E3 ligase SKP2 and DUB OTUD1, YAP undergoes K63-linked polyubiquitination to determine its nuclear translocation and activity. Blocking the K63 modification of YAP greatly inhibiting the MDA-MB-231 cell proliferation <ce:cross-ref id="crf0310" refid="bib0175">[35]</ce:cross-ref>.</ce:para>
                     <ce:para id="par0110" view="all">Different from promoting protein proteolysis, targeting nonproteolytic ubiquitination represented a breakthrough in the regulation of TF function and a significant and important therapeutic avenue. However, most investigations mainly focused on degradative outcomes of ubiquitination and, because of the nebulous mechanism involved, there have been few viable dug candidates.</ce:para>
                  </ce:section>
               </ce:section>
               <ce:section id="sec0045" view="all">
                  <ce:section-title id="sect0050">Targeting TF phosphorylation</ce:section-title>
                  <ce:para id="par0115" view="all">In addition to ubiquitination, TF phosphorylation also has a crucial role in signal transduction, cell growth, and division for various diseases, including cancer. Rapidly reversible phosphorylation via protein kinases and phosphatases transduces extracellular signals into the nucleus, which is accompanied by changes in the subcellular translocation, stability, and activity of TFs. Chemically, phosphate group forms an ester bond mainly with Ser, Thr, and Tyr amino acids residues, resulting in electrical and conformational changes, thereby modifying substrate affinity with DNA or other proteins <ce:cross-ref id="crf0315" refid="bib0020">[4]</ce:cross-ref>. Thus, manipulating TFs by regulating their phosphorylation states become a credible strategy.</ce:para>
                  <ce:section id="sec0050" view="all">
                     <ce:section-title id="sect0055">Inhibiting phosphorylation to attenuate TFs activity</ce:section-title>
                     <ce:para id="par0120" view="all">Phosphokinases, including Janus kinases (JAKs), tyrosine-protein kinase, and protein kinase B (AKT), are main regulators of TF phosphorylation. STATs become activated through tyrosine phosphorylation, which is typically mediated by JAKs and tyrosine kinases in most malignancies. Phosphorylated STATs translocate into nucleus and have an important role in cytokine-driven signaling. Recently, considerable progress has been made in efforts to develop phosphorylated STAT-targeted therapeutic agents. Jang et al. isolated an anticancer compound ECN from <ce:italic>Flos farfarae</ce:italic> that significantly inhibits phosphorylation of STAT3 at Tyr705 by decreasing the phosphorylation and activities of JAK1, JAK2, and Src (<ce:cross-ref id="crf0320" refid="fig0015">Fig. 3</ce:cross-ref>
                        <ce:float-anchor refid="fig0015"/></ce:float-anchor>A), showing a potent cytotoxic effect against MDA-MB-231 cells <ce:cross-ref id="crf0325" refid="bib0180">[36]</ce:cross-ref>. Nagathihalli et al. also verified STAT3 as a biomarker of therapeutic resistance for pancreatic ductal adenocarcinoma. They used AZD1480, a JAK selective inhibitor, combined with gemcitabine to enhance <ce:italic>in vivo</ce:italic> drug delivery and improve survival in luciferase-tagged PANC1 cell-induced orthotopic xenograft mouse models and <ce:italic>Ptf1a<ce:sup loc="post">cre/+</ce:sup>
                        </ce:italic>;<ce:italic>LSL-Kras<ce:sup loc="post">G12D/+</ce:sup>
                        </ce:italic>;<ce:italic>Tgfbr2<ce:sup loc="post">flox/flox</ce:sup>
                        </ce:italic> (PKT) mice <ce:cross-ref id="crf0330" refid="bib0185">[37]</ce:cross-ref>. The aberrant regulation of the tyrosine phosphorylation network is a hallmark of breast cancer progression from initiation to metastasis <ce:cross-ref id="crf0335" refid="bib0190">[38]</ce:cross-ref>. Except for STAT3, the TF E-twenty six 1 (ETS1), which is also responsible for unfavorable prognosis in triple-negative breast carcinoma, is reported to be phosphorylated by Src family kinase. Such PTM disrupts the binding of the tumor suppressor protein constitutively photomorphogenic 1 (COP1) and inhibits its destruction. Lu et al. found that the Src kinase inhibitor dasatinib decreased both ETS1 tyrosine phosphorylation and protein abundance in MDA-MB-231 cells <ce:cross-ref id="crf0340" refid="bib0195">[39]</ce:cross-ref>. AKT-mediated phosphorylation also significantly affects the activities of TFs. ZNF322A is an oncogenic zinc-finger TF in lung cancer. AKT phosphorylates ZNF332A at Thr150, Ser224, Thr234, and Thr262 to promote its protein stability and transcription activity, which was attenuated by the inhibitor MK2206 at 10<ce:hsp sp="0.25"/></ce:hsp>μM <ce:cross-ref id="crf0345" refid="bib0200">[40]</ce:cross-ref>.</ce:para>
                     <ce:para id="par0125" view="all">Except for phosphokinases, which are phosphorylated and activated by transforming growth factor beta (TGF-β), the SMAD signaling cascade is the primary cause of epithelial-to-mesenchymal transition (EMT) and metastasis. Nutlin-3 decreases the transcription of Snail and Slug and prohibits EMT by interfering with the canonical TGF-β1–SMAD axis and blocking Smad2/3 phosphorylation (<ce:cross-ref id="crf0350" refid="fig0015">Fig. 3</ce:cross-ref>A). Based on this mechanism, Nutlin-3 was also shown to sensitize EGFR inhibitors gefitinib and lapatinib with potentiated anticancer activity <ce:cross-ref id="crf0355" refid="bib0205">[41]</ce:cross-ref>.</ce:para>
                     <ce:para id="par0130" view="all">With the revolution of cancer therapeutics, phosphokinases are regarded as one of the targets with the most therapeutic potential because of their well-determined active pockets. Although considerable progress has been made in the development of kinase inhibitors, our understanding of TF phosphorylation is only the tip of the iceberg.</ce:para>
                  </ce:section>
                  <ce:section id="sec0055" view="all">
                     <ce:section-title id="sect0060">Promoting phosphorylation to inhibit TF activity</ce:section-title>
                     <ce:para id="par0135" view="all">Among the many TFs and cofactors regulated by phosphorylation, YAP and TAZ have received significant research attention. Negatively regulated by the canonical Hippo pathway, YAP/TAZ is phosphorylated at Ser127 by large tumor suppressor 1/2 (LATS1/2), which sequesters YAP/TAZ in the cytoplasm for ubiquitination degradation <ce:cross-ref id="crf0360" refid="bib0210">[42]</ce:cross-ref>. Many studies have implicated the role of YAP in sorafenib and irinotecan resistance under hypoxia. Mechanically, hypoxia diminishes YAP phosphorylation and promotes YAP nucleus translocation <ce:cross-ref id="crf0365" refid="bib0215">[43]</ce:cross-ref>. Statins, a class of specific 3-hydroxymethylglutaryl-CoA reductase (HMGCR) inhibitors, significantly rescue hypoxia-mediated loss of YAP phosphorylation and the activation of YAP target genes to counteract the hypoxia-mediated above resistance <ce:cross-ref id="crf0370" refid="bib0220">[44]</ce:cross-ref> (<ce:cross-ref id="crf0375" refid="fig0015">Fig. 3</ce:cross-ref>B). More excitingly, a National Medical Products Administration (NMPA)-approved multi-kinase inhibitor, C-T707, was identified that has remarkable inhibitory activity against YAP functions independent of HIF-1α under hypoxia. By interrupting the insulin-like growth factor 1 receptor (IGF1R)–YAP axis, CT-707 causes a significant increase in p-YAP (S127) with the loss of total protein abundance in HCC <ce:cross-ref id="crf0380" refid="bib0225">[45]</ce:cross-ref>.</ce:para>
                     <ce:para id="par0140" view="all">In addition to YAP, the phosphorylation of Myc is another classic example of transcriptional activity inhibition. It can be phosphorylated at Ser62 by kinases cascades, such as c-Jun N-terminal kinase (c-JNK), mitogen-activated extracellular signal-regulated kinase (MEK), and cyclin-dependent kinases (CDK), following with Thr58 phosphorylation by glycogen synthase kinase-3β (GSK3β) and degradation by 26S proteasome <ce:cross-refs id="crfs0065" refid="bib0230 bib0235">[46,47]</ce:cross-refs>. Han et al. developed two Myc inhibitors, 361 and 975, which not only disrupted Myc/Max active dimers, but also enhanced Myc T58 phosphorylation without impacting the GSK3β off-target, consequently triggering proteasome-mediated degradation <ce:cross-ref id="crf0385" refid="bib0235">[47]</ce:cross-ref>. Compound 975 not only inhibited tumor progression, but also increased immune cell infiltration and, thus, potentiates anti-PD1 immunotherapy. Although the underlying mechanisms of how compounds 361 and 975 caused T58 phosphorylation remain unclear, the significant <ce:italic>in vivo</ce:italic> efficacy of 975 in particular is clear <ce:cross-ref id="crf0390" refid="bib0235">[47]</ce:cross-ref>.</ce:para>
                     <ce:para id="par0145" view="all">Thus, phosphorylation can degrade TFs to inhibit tumor progression. However, unlike the kinases inhibitors mentioned earlier, promoting TF phosphorylation remains challenging because of our limited knowledge of phosphatases and the difficulties associated with developing protein kinase-activating compounds. Thus, new approaches and technologies, such as allosteric regulation, could provide new opportunities in this field.</ce:para>
                  </ce:section>
               </ce:section>
               <ce:section id="sec0060" view="all">
                  <ce:section-title id="sect0065">Targeting TF acetylation</ce:section-title>
                  <ce:para id="par0150" view="all">Hypo- or hyperacetylation of oncoproteins caused by dysregulation of histone deacetylase (HDAC) and histone acetyltransferase (HAT) have been detected in various solid tumors (endometrial, lung, liver, etc.) and hematological tumors (AML, CLL, and myeloma) <ce:cross-ref id="crf0395" refid="bib0240">[48]</ce:cross-ref>. The first report of p53 as a nonhistone target of HAT has been followed by numerous others, the largest class of which are TFs. Previous studies demonstrated that p53 is activated by acetylation on lysine residues at the DNA-binding domain through p300/ CREB-binding protein (CBP) <ce:cross-ref id="crf0400" refid="bib0245">[49]</ce:cross-ref>. p53 acetylation prevents its ubiquitination degradation because the acetylated lysine residues overlap with ubiquitinated residues. In addition, HDAC1 and sirtuin1 (SIRT1) are recognized as p53 deacetylases <ce:cross-ref id="crf0405" refid="bib0250">[50]</ce:cross-ref>. Wang et al. reported that mutation of four acetylation sites (K98R, K117R, K161R, and K162R) on p53 (p53<ce:sup loc="post">4KR</ce:sup>) reduced the tumor suppressor ability of p53 in mouse xenograft models. Moreover, the p53-dependent ferroptosis response is abrogated by p53<ce:sup loc="post">4KR</ce:sup> 
                     <ce:cross-ref id="crf0410" refid="bib0255">[51]</ce:cross-ref>. De et al. reported that the novel SIRT inhibitor, MHY2256 significantly increases p53 acetylation (<ce:cross-ref id="crf0415" refid="fig0020">Fig. 4</ce:cross-ref>
                     <ce:float-anchor refid="fig0020"/></ce:float-anchor>A), inducing apoptosis in endometrial cancer cells <ce:cross-ref id="crf0420" refid="bib0260">[52]</ce:cross-ref>. Although the acetylation activation of p53 increases the antitumor effect, the chemotoxicity caused by p53 overactivation remains an issue. Zheng et al. discovered that, as a reversible p300 inhibitor, C646 blocks acetylation of p53 and downregulates its transcriptional activity to protect normal bone marrow cells from doxorubicin-induced toxicity <ce:cross-ref id="crf0425" refid="bib0265">[53]</ce:cross-ref>.</ce:para>
                  <ce:para id="par0155" view="all">In addition to p53, Snail is also reported to be acetylated by CBP at Lys146 and Lys187, followed by the transactivation of target genes, <ce:italic>TNFa</ce:italic>, <ce:italic>CCL2</ce:italic>, and <ce:italic>CCL5</ce:italic>m to remodel the tumor microenvironment. As shown in <ce:cross-ref id="crf0430" refid="fig0020">Fig. 4</ce:cross-ref>A, the HAT inhibitor C646 also shows inhibitory activity against CBP and abrogates Snail-mediated gene expression <ce:cross-ref id="crf0435" refid="bib0270">[54]</ce:cross-ref>. The Myc oncogene is also deemed to be a crucial HDACi target. Nebbioso et al. confirmed that c-Myc binds to the promoter of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), leading to its quiescent in AML cells, while two HDAC inhibitors, MS27−275 (entinostat) and SAHA (vorinostat), induce c-Myc acetylation at Lys323 and decrease its protein level, disrupting the binding of c-Myc–<ce:italic>TRAIL</ce:italic> 
                     <ce:cross-ref id="crf0440" refid="bib0275">[55]</ce:cross-ref>. Thus, HDACi exposure triggers TRAIL expression in AML blasts and primary human breast cancer cells to exert an anticancer effect mainly through c-Myc modulation.</ce:para>
                  <ce:para id="par0160" view="all">Compared with ubiquitination and phosphorylation, the acetylation of proteins is much discussed in the field of epigenetics, and the acetylation of TFs remains elusive. Currently, there are many HDACis undergoing clinical investigation either alone or in combination with other therapeutic modalities. Those candidates are not only relevant against solid malignancies, but also as hematological therapies. Although it remains unclear whether these compounds can be used clinically to treat TF-addicted tumors, targeting TF acetylation has clear advantages.</ce:para>
               </ce:section>
               <ce:section id="sec0065" view="all">
                  <ce:section-title id="sect0070">Targeting TF methylation</ce:section-title>
                  <ce:para id="par0165" view="all">So far, the biological and physiological significance of methylation in human tumorigenesis has been explored in lung cancer, colorectal cancer, and HCC, among others <ce:cross-ref id="crf0445" refid="bib0280">[56]</ce:cross-ref>. Similar to acetylation, early studies of TF methylation focused on histones, until p53 became the first nonhistone protein/TF reported to be methylated and regulated by lysine methyltransferase Set7/9 <ce:cross-ref id="crf0450" refid="bib0285">[57]</ce:cross-ref>. Accumulating evidence suggests that Set9 can modulate many TFs, including STAT3, HIF1-α, and RAR, but the corresponding inhibitors are remain elusive <ce:cross-refs id="crfs0070" refid="bib0290 bib0295">[58,59]</ce:cross-refs>. Some new compounds, such as DC-S238 and DC-S239, have been developed <ce:cross-ref id="crf0455" refid="bib0300">[60]</ce:cross-ref>. In addition, TFs are also subject to methylation by other methylases. Chae et al. reported that forkhead family TF 1 (FOXO1) is methylated by G9a at K273 residue, accelerating its interaction with E3 ligase SKP2 and protein degradation to promote colon cancer cell proliferation, which can be counteracted by the G9a-specific inhibitor, BIX01294 (<ce:cross-ref id="crf0460" refid="fig0020">Fig. 4</ce:cross-ref>B) <ce:cross-ref id="crf0465" refid="bib0305">[61]</ce:cross-ref>.</ce:para>
                  <ce:para id="par0170" view="all">Methylation can occur on all basic residues (mainly arginines, lysines, and histidines), increasing its universality and uncertainty <ce:cross-ref id="crf0470" refid="bib0020">[4]</ce:cross-ref>. For those histone proteins, clinically advanced DNA-hypomethylating agents have been developed, such as azacitidine and decitabine. However, for these nonhistone proteins, the multiplicity and ambiguity of methylation modifications might be one of the barriers to the research and development of related inhibitors <ce:cross-ref id="crf0475" refid="bib0310">[62]</ce:cross-ref>.</ce:para>
               </ce:section>
               <ce:section id="sec0070" view="all">
                  <ce:section-title id="sect0075">Targeting TF sumoylation</ce:section-title>
                  <ce:para id="par0175" view="all">Sumoylation is another reversible cascade modified by small ubiquitin-like modifier (SUMO) through the E1 activating enzyme SAE1/2, E2-conjugating enzyme Ubc9, and substrate-specific E3 ligases <ce:cross-ref id="crf0480" refid="bib0315">[63]</ce:cross-ref>. Sumoylation is reported to be upregulated when there are intrinsic and extrinsic stresses. Given that many cancers exhibit substantially enhanced sumoylation, researchers speculate that tumor cells demand such modification to mitigate or restrain stress responses, such as inflammation <ce:cross-ref id="crf0485" refid="bib0315">[63]</ce:cross-ref>. TFs are among the most frequently detected targets of sumoylation.</ce:para>
                  <ce:para id="par0180" view="all">The initial link between TF sumoylation and tumor development was provided by PML-RARα. This fusion protein causes a hematological malignancy termed acute promyelocytic leukaemia (APL), which can be treated by trivalent arsenic compounds and all-<ce:italic>trans</ce:italic> retinoic acid. Arsenic treatment stimulates PML-dependent hypersumoylation, which in turn leads to the recruitment of the SUMO-dependent E3 ubiquitin-ligase RNF4 and proteasomal degradation to restore PML nuclear body integrity (<ce:cross-ref id="crf0490" refid="fig0020">Fig. 4</ce:cross-ref>C) <ce:cross-ref id="crf0495" refid="bib0320">[64]</ce:cross-ref>.</ce:para>
                  <ce:para id="par0185" view="all">Despite current understanding of TF sumoylation, gaps remain to be filled. One paradigmatic example is the relationship between sumoylation and c-Myc oncoprotein. Early in 2012, Kessler et al. reported the discovery of the sumo-activating enzyme, SAE1/2, which can cause defective sumoylation, switching the transcriptional subprogram of Myc from activation to repression, leading to mitotic catastrophe and cell death <ce:cross-ref id="crf0500" refid="bib0325">[65]</ce:cross-ref>. Then, He et al. identified a selective SAE inhibitor ML-792, which is synthetic lethal with Myc overexpression in SK-MEL-28 cells (<ce:cross-ref id="crf0505" refid="fig0020">Fig. 4</ce:cross-ref>D) <ce:cross-ref id="crf0510" refid="bib0330">[66]</ce:cross-ref>. González-Prieto et al. demonstrated that sumoylation is required to counteract excessive c-Myc activity <ce:cross-ref id="crf0515" refid="bib0335">[67]</ce:cross-ref>. Both the knockdown of RNF4 or sumo E3 ligase PIAS1 results in reduced c-Myc degradation, which indicates that impaired sumoylation switches c-Myc from being repressed to being overactivated. This can be explained by the higher substrate specificity of RNF4 and PIAS and the broader impacts of SAE inhibition. Meanwhile, these features also imply that total or local inhibition effects result in different outcomes.</ce:para>
                  <ce:para id="par0190" view="all">Although small molecules (such as anacardic acid and COH000) that target the E1 and E2 enzymes to globally inhibit sumoylation have reduced tumor burden in HCT-116 cell-induced xenograft mouse models, it is unknown whether the totally pharmacological impairment of the sumo system has risks because of the complexity of sumoylation and the elusive tumor microenvironment <ce:cross-ref id="crf0520" refid="bib0340">[68]</ce:cross-ref>. Given that sumoylation subsequently triggers further PTMs, such as ubiquitination, phosphorylation, and acetylation, targeting the sumoylation of tumor-specific TFs could lead to a butterfly effect, resulting in tumor cell death.</ce:para>
               </ce:section>
               <ce:section id="sec0075" view="all">
                  <ce:section-title id="sect0080">Concluding remarks and future perspectives</ce:section-title>
                  <ce:para id="par0195" view="all">The concept of transcription addiction has been proposed based on current research. This emphasizes the essential role of dysregulated transcriptional programs in multistep tumorigenesis. Not surprisingly, the identification of TF drivers in malignancies has attracted considerable attention. However, owing to their undruggability, no drugs have yet entered clinical use (except for those targeting nuclear receptors). It is clear from the success stories detailed in this review that the PTMs of TFs are common in various tumors and expand the scalability of TFs<ce:hsp sp="0.25"/></ce:hsp>=<ce:hsp sp="0.25"/></ce:hsp>regulation. There are some unique advantages. First, the regulators of PTMs are mostly enzymes, which are more accessible to be targeted by small molecules with high specificity. Second, some PTMs, such as sumoylation, are deregulated significantly under pathological conditions, which could offer a new therapeutic window to target.</ce:para>
                  <ce:para id="par0200" view="all">Various TFs appear to operate in specific subsets of cancer, which might depend on the location of the primary tumor and its heterogeneity. This means that targeting TF PTMs might exhibit different therapeutic effects. For instance, it is likely that fusion protein PML-RARα is vital for the early development and ongoing viability of leukemia, but no studies have reported the occurrence of this fusion in solid tumors. Thus, targeting the PTMs of PML-RARα will be specific for patients with leukemia. By contrast, dysregulation of Myc is common in most human cancers. Researches have validated the addiction of this master TF in different solid tumors. Therefore, targeting PTMs of Myc will be responsive in a variety of tumors. In addition, the same TF can have multiple PTMs. There is no established principle to elucidate which PTM is most important. evolving techniques, such as highly sensitive mass spectrometry and sequencing techniques, could provide more scientific support for the further exploration of PTM-based TF targeting in cancer therapy.</ce:para>
                  <ce:para id="par0205" view="all">Exciting data are emerging that the ability to orchestrate the undruggable proteome is one of the most promising aspects of PTM-based TF targeting and could provide a path to overcome existing challenges in anticancer drug development. Based on such a principle, a large number of novel approaches are worth testing to explore novel agents that substantially improve treatment outcomes. This novel therapeutic modality could provide substantial and meaningful efficacy. Meanwhile, it will be vital to extend the clinical application of conventional drugs or to overcome resistance through combining TF PTM-targeted compounds with traditional chemotherapeutic agents.</ce:para>
               </ce:section>
               <ce:section id="sec0080" view="all">
                  <ce:section-title id="sect0085">Declaration of Competing Interest</ce:section-title>
                  <ce:para id="par0210" view="all">The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</ce:para>
               </ce:section>
            </ce:sections>
            <ce:acknowledgment id="ack0005" view="all">
               <ce:section-title id="sect0090">Acknowledgments</ce:section-title>
               <ce:para id="par0215" view="all">This work was supported by the <ce:grant-sponsor id="gs0005" sponsor-id="https://doi.org/10.13039/501100001809" xlink:type="simple" xlink:role="http://www.elsevier.com/xml/linking-roles/grant-sponsor">National Natural Science Foundation of China</ce:grant-sponsor> (<ce:grant-number refid="gs0005">81830107</ce:grant-number>) to Q.H., <ce:grant-sponsor id="gs0010" sponsor-id="https://doi.org/10.13039/501100001809" xlink:type="simple" xlink:role="http://www.elsevier.com/xml/linking-roles/grant-sponsor">National Natural Science Foundation of China</ce:grant-sponsor> (<ce:grant-number refid="gs0010">81973349</ce:grant-number>) to H.Z., and the <ce:grant-sponsor id="gs0015" sponsor-id="https://doi.org/10.13039/501100004731" xlink:type="simple" xlink:role="http://www.elsevier.com/xml/linking-roles/grant-sponsor">Natural Science Foundation of Zhejiang Province</ce:grant-sponsor> (no. <ce:grant-number refid="gs0015">LR19H310002</ce:grant-number>) to H.Z.</ce:para>
            </ce:acknowledgment>
         </body>
         <tail view="all">
            <ce:bibliography id="bibl0005" view="all">
               <ce:section-title id="sect0095">References</ce:section-title>
               <ce:bibliography-sec id="bibs0005" view="all">
                  <ce:bib-reference id="bib0005">
                     <ce:label>1</ce:label>
                     <sb:reference id="sbref0005">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.H.</ce:given-name>
                                 <ce:surname>Bushweller</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Targeting transcription factors in cancer - from undruggable to reality</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Nat. Rev. Cancer</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>19</sb:volume-nr>
                              </sb:series>
                              <sb:date>2019</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>611</sb:first-page>
                              <sb:last-page>624</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0010">
                     <ce:label>2</ce:label>
                     <sb:reference id="sbref0010">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Bradner</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Transcriptional addiction in cancer</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Cell</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>168</sb:volume-nr>
                              </sb:series>
                              <sb:date>2017</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>629</sb:first-page>
                              <sb:last-page>643</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0015">
                     <ce:label>3</ce:label>
                     <sb:reference id="sbref0015">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Hagenbuchner</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.J.</ce:given-name>
                                 <ce:surname>Ausserlechner</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Targeting transcription factors by small compounds-current strategies and future implications</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Biochem. Pharmacol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>107</sb:volume-nr>
                              </sb:series>
                              <sb:date>2016</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1</sb:first-page>
                              <sb:last-page>13</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0020">
                     <ce:label>4</ce:label>
                     <sb:reference id="sbref0020">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>T.M.</ce:given-name>
                                 <ce:surname>Filtz</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Regulation of transcription factor activity by interconnected post-translational modifications</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Trends Pharmacol. Sci.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>35</sb:volume-nr>
                              </sb:series>
                              <sb:date>2014</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>76</sb:first-page>
                              <sb:last-page>85</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0025">
                     <ce:label>5</ce:label>
                     <sb:reference id="sbref0025">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Popovic</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Ubiquitination in disease pathogenesis and treatment</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Nat. Med.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>20</sb:volume-nr>
                              </sb:series>
                              <sb:date>2014</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1242</sb:first-page>
                              <sb:last-page>1253</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0030">
                     <ce:label>6</ce:label>
                     <sb:reference id="sbref0030">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Liu</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Targeting the ubiquitin pathway for cancer treatment</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Biochim. Biophys. Acta</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>1855</sb:volume-nr>
                              </sb:series>
                              <sb:date>2015</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>50</sb:first-page>
                              <sb:last-page>60</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0035">
                     <ce:label>7</ce:label>
                     <sb:reference id="sbref0035">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>L.H.</ce:given-name>
                                 <ce:surname>Gallo</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>The importance of regulatory ubiquitination in cancer and metastasis</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Cell Cycle</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>16</sb:volume-nr>
                              </sb:series>
                              <sb:date>2017</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>634</sb:first-page>
                              <sb:last-page>648</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0040">
                     <ce:label>8</ce:label>
                     <sb:reference id="sbref0040">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>E3 ubiquitin ligases in cancer and implications for therapies</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Cancer Meta. Rev.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>36</sb:volume-nr>
                              </sb:series>
                              <sb:date>2017</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>683</sb:first-page>
                              <sb:last-page>702</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0045">
                     <ce:label>9</ce:label>
                     <sb:reference id="sbref0045">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Lemos</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Medicinal chemistry strategies to disrupt the p53-MDM2/MDMX interaction</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Med. Res. Rev.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>36</sb:volume-nr>
                              </sb:series>
                              <sb:date>2016</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>789</sb:first-page>
                              <sb:last-page>844</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0050">
                     <ce:label>10</ce:label>
                     <sb:reference id="sbref0050">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>The pyridobindole MDM2 inhibitor SP-141 exerts potent therapeutic effects in breast cancer models</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Nat Commun.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>5</sb:volume-nr>
                              </sb:series>
                              <sb:date>2014</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>5086</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0055">
                     <ce:label>11</ce:label>
                     <sb:reference id="sbref0055">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Andreeff</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Results of the Phase I trial of RG7112, a small-molecule MDM2 antagonist in leukemia</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Clin. Cancer Res.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>22</sb:volume-nr>
                              </sb:series>
                              <sb:date>2016</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>868</sb:first-page>
                              <sb:last-page>876</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0060">
                     <ce:label>12</ce:label>
                     <sb:reference id="sbref0060">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>N.G.</ce:given-name>
                                 <ce:surname>Her</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Potent effect of the MDM2 inhibitor AMG232 on suppression of glioblastoma stem cells</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Cell Death Dis.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>9</sb:volume-nr>
                              </sb:series>
                              <sb:date>2018</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>792</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0065">
                     <ce:label>13</ce:label>
                     <sb:reference id="sbref0065">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Reuther</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>The HDM2 (MDM2) inhibitor NVP-CGM097 inhibits tumor cell proliferation and shows additive effects with 5-fluorouracil on the p53-p21-Rb-E2F1 cascade in the p53wild type neuroendocrine tumor cell line GOT1</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Neuroendocrinology</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>106</sb:volume-nr>
                              </sb:series>
                              <sb:date>2018</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1</sb:first-page>
                              <sb:last-page>19</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0070">
                     <ce:label>14</ce:label>
                     <sb:reference id="sbref0070">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Ying</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>The E3 ubiquitin protein ligase MDM2 dictates all-trans retinoic acid-induced osteoblastic differentiation of osteosarcoma cells by modulating the degradation of RARalpha</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Oncogene</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>35</sb:volume-nr>
                              </sb:series>
                              <sb:date>2016</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>4358</sb:first-page>
                              <sb:last-page>4367</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0075">
                     <ce:label>15</ce:label>
                     <sb:reference id="sbref0075">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Gandolfi</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>The proteasome and proteasome inhibitors in multiple myeloma</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Cancer Meta. Rev.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>36</sb:volume-nr>
                              </sb:series>
                              <sb:date>2017</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>561</sb:first-page>
                              <sb:last-page>584</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0080">
                     <ce:label>16</ce:label>
                     <sb:reference id="sbref0080">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>D.S.</ce:given-name>
                                 <ce:surname>Das</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Blockade of deubiquitylating enzyme USP1 inhibits DNA repair and triggers apoptosis in multiple myeloma cells</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Clin. Cancer Res.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>23</sb:volume-nr>
                              </sb:series>
                              <sb:date>2017</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>4280</sb:first-page>
                              <sb:last-page>4289</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0085">
                     <ce:label>17</ce:label>
                     <sb:reference id="sbref0085">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.K.</ce:given-name>
                                 <ce:surname>Lee</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>USP1 targeting impedes GBM growth by inhibiting stem cell maintenance and radioresistance</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Neuro. Oncol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>18</sb:volume-nr>
                              </sb:series>
                              <sb:date>2016</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>37</sb:first-page>
                              <sb:last-page>47</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0090">
                     <ce:label>18</ce:label>
                     <sb:reference id="sbref0090">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Ubiquitin-specific protease-7 inhibition impairs Tip60-dependent Foxp3+ T-regulatory cell function and promotes antitumor immunity</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>EBioMedicine</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>13</sb:volume-nr>
                              </sb:series>
                              <sb:date>2016</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>99</sb:first-page>
                              <sb:last-page>112</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0095">
                     <ce:label>19</ce:label>
                     <sb:reference id="sbref0095">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Liu</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Inhibition of the deubiquitinase USP9x induces pre-B cell homeobox 1 (PBX1) degradation and thereby stimulates prostate cancer cell apoptosis</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Biol. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>294</sb:volume-nr>
                              </sb:series>
                              <sb:date>2019</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>4572</sb:first-page>
                              <sb:last-page>4582</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0100">
                     <ce:label>20</ce:label>
                     <sb:reference id="sbref0100">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Yuan</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Deubiquitinating enzyme USP10 promotes hepatocellular carcinoma metastasis through deubiquitinating and stabilizing Smad4 protein</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Mol. Oncol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>14</sb:volume-nr>
                              </sb:series>
                              <sb:date>2020</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>197</sb:first-page>
                              <sb:last-page>210</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0105">
                     <ce:label>21</ce:label>
                     <sb:reference id="sbref0105">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.A.</ce:given-name>
                                 <ce:surname>Harrigan</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Deubiquitylating enzymes and drug discovery: emerging opportunities</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Nat. Rev. Drug Discov.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>17</sb:volume-nr>
                              </sb:series>
                              <sb:date>2018</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>57</sb:first-page>
                              <sb:last-page>78</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0110">
                     <ce:label>22</ce:label>
                     <sb:reference id="sbref0110">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Verma</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Harnessing the power of proteolysis for targeted protein inactivation</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Mol. Cell.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>77</sb:volume-nr>
                              </sb:series>
                              <sb:date>2020</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>446</sb:first-page>
                              <sb:last-page>460</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0115">
                     <ce:label>23</ce:label>
                     <sb:reference id="sbref0115">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Degradation of proteins by PROTACs and other strategies</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Acta Pharm. Sin. B</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>10</sb:volume-nr>
                              </sb:series>
                              <sb:date>2020</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>207</sb:first-page>
                              <sb:last-page>238</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0120">
                     <ce:label>24</ce:label>
                     <sb:reference id="sbref0120">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Sun</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>BET protein proteolysis targeting chimera (PROTAC) exerts potent lethal activity against mantle cell lymphoma cells</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Leukemia</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>32</sb:volume-nr>
                              </sb:series>
                              <sb:date>2018</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>343</sb:first-page>
                              <sb:last-page>352</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0125">
                     <ce:label>25</ce:label>
                     <sb:reference id="sbref0125">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:surname>Arvinas</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>A Phase 1 clinical trial of ARV-110 in patients with metastatic castration-resistant prostate cancer (mCRPC)</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:book>
                              <sb:date>2019</sb:date>
                           </sb:book>
                        </sb:host>
                        <sb:comment>(Accessed 26 May 2020)</sb:comment>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref id="intr0005" xlink:role="http://www.elsevier.com/xml/linking-roles/preprint" xlink:href="arxiv:/www.clinicaltrials.gov/ct2/show/NCT03888612.2020" xlink:type="simple">www.clinicaltrials.gov/ct2/show/NCT03888612.2020</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0130">
                     <ce:label>26</ce:label>
                     <sb:reference id="sbref0130">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:surname>Arvinas</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>ARV-471, an ER-Targeting Protein Degrader For Breast Cancer</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:book>
                              <sb:date>2020</sb:date>
                              <sb:publisher>
                                 <sb:name>Arvinas</sb:name>
                              </sb:publisher>
                           </sb:book>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0135">
                     <ce:label>27</ce:label>
                     <sb:reference id="sbref0135">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Scudellari</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Protein-slaying drugs could be the next blockbuster therapies</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Nature</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>567</sb:volume-nr>
                              </sb:series>
                              <sb:date>2019</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>298</sb:first-page>
                              <sb:last-page>300</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0140">
                     <ce:label>28</ce:label>
                     <sb:reference id="sbref0140">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Bai</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>A potent and selective small-molecule degrader of STAT3 achieves complete tumor regression in vivo</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Cancer Cell</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>36</sb:volume-nr>
                              </sb:series>
                              <sb:date>2019</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>498</sb:first-page>
                              <sb:last-page>511</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0145">
                     <ce:label>29</ce:label>
                     <sb:reference id="sbref0145">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>L.N.</ce:given-name>
                                 <ce:surname>Heppler</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.A.</ce:given-name>
                                 <ce:surname>Frank</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Inhibit versus destroy: are PROTAC degraders the solution to targeting STAT3?</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Cancer Cell</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>36</sb:volume-nr>
                              </sb:series>
                              <sb:date>2019</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>459</sb:first-page>
                              <sb:last-page>461</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0150">
                     <ce:label>30</ce:label>
                     <sb:reference id="sbref0150">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Cicconi</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Molecular remission as a therapeutic objective in acute promyelocytic leukemia</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Leukemia</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>32</sb:volume-nr>
                              </sb:series>
                              <sb:date>2018</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1671</sb:first-page>
                              <sb:last-page>1678</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0155">
                     <ce:label>31</ce:label>
                     <sb:reference id="sbref0155">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Kronke</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Science</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>343</sb:volume-nr>
                              </sb:series>
                              <sb:date>2014</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>301</sb:first-page>
                              <sb:last-page>305</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0160">
                     <ce:label>32</ce:label>
                     <sb:reference id="sbref0160">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>Q.L.</ce:given-name>
                                 <ce:surname>Sievers</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Petzold</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Defining the human C2H2 zinc finger degrome targeted by thalidomide analogs through CRBN</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Science</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>362</sb:volume-nr>
                              </sb:series>
                              <sb:date>2018</sb:date>
                           </sb:issue>
                        </sb:host>
                        <sb:comment>eaat0572</sb:comment>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0165">
                     <ce:label>33</ce:label>
                     <sb:reference id="sbref0165">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.A.</ce:given-name>
                                 <ce:surname>Dimopoulos</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Safety and efficacy of pomalidomide plus low-dose dexamethasone in STRATUS (MM-010): a phase 3b study in refractory multiple myeloma</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Blood</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>128</sb:volume-nr>
                              </sb:series>
                              <sb:date>2016</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>497</sb:first-page>
                              <sb:last-page>503</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0170">
                     <ce:label>34</ce:label>
                     <sb:reference id="sbref0170">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>V.</ce:given-name>
                                 <ce:surname>Glorian</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>DNA damage and S phase-dependent E2F1 stabilization requires the cIAP1 E3-ubiquitin ligase and is associated with K63-poly–ubiquitination on lysine 161/164 residues</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Cell Death Dis.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>8</sb:volume-nr>
                              </sb:series>
                              <sb:date>2017</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>e2816</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0175">
                     <ce:label>35</ce:label>
                     <sb:reference id="sbref0175">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Yao</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>SKP2- and OTUD1-regulated non-proteolytic ubiquitination of YAP promotes YAP nuclear localization and activity</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Nat. Commun.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>9</sb:volume-nr>
                              </sb:series>
                              <sb:date>2018</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>2269</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0180">
                     <ce:label>36</ce:label>
                     <sb:reference id="sbref0180">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Jang</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>A sesquiterpenoid from Farfarae Flos induces apoptosis of MDA-MB-231 human breast cancer cells through inhibition of JAK–STAT3 signaling</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Biomolecules</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>9</sb:volume-nr>
                              </sb:series>
                              <sb:date>2019</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>278</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0185">
                     <ce:label>37</ce:label>
                     <sb:reference id="sbref0185">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>N.S.</ce:given-name>
                                 <ce:surname>Nagathihalli</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Signal transducer and activator of transcription 3, mediated remodeling of the tumor microenvironment results in enhanced tumor drug delivery in a mouse model of pancreatic cancer</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Gastroenterology</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>149</sb:volume-nr>
                              </sb:series>
                              <sb:date>2015</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1932</sb:first-page>
                              <sb:last-page>1943</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0190">
                     <ce:label>38</ce:label>
                     <sb:reference id="sbref0190">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.R.</ce:given-name>
                                 <ce:surname>Ha</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>The tyrosine kinome dictates breast cancer heterogeneity and therapeutic responsiveness</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J Cell Biochem</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>117</sb:volume-nr>
                              </sb:series>
                              <sb:date>2016</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1971</sb:first-page>
                              <sb:last-page>1990</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0195">
                     <ce:label>39</ce:label>
                     <sb:reference id="sbref0195">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Lu</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Phosphorylation of ETS1 by Src family kinases prevents its recognition by the COP1 tumor suppressor</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Cancer Cell</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>26</sb:volume-nr>
                              </sb:series>
                              <sb:date>2014</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>222</sb:first-page>
                              <sb:last-page>234</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0200">
                     <ce:label>40</ce:label>
                     <sb:reference id="sbref0200">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>S.Y.</ce:given-name>
                                 <ce:surname>Liao</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>AKT-mediated phosphorylation enhances protein stability and transcription activity of ZNF322A to promote lung cancer progression</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Oncogene</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>38</sb:volume-nr>
                              </sb:series>
                              <sb:date>2019</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>6723</sb:first-page>
                              <sb:last-page>6736</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0205">
                     <ce:label>41</ce:label>
                     <sb:reference id="sbref0205">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Wu</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Nutlin-3 inhibits epithelial-mesenchymal transition by interfering with canonical transforming growth factor-beta1-Smad-Snail/Slug axis</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Cancer Lett.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>342</sb:volume-nr>
                              </sb:series>
                              <sb:date>2014</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>82</sb:first-page>
                              <sb:last-page>91</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0210">
                     <ce:label>42</ce:label>
                     <sb:reference id="sbref0210">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Maugeri-Sacca</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>De Maria</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>The Hippo pathway in normal development and cancer</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Pharmacol. Ther.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>186</sb:volume-nr>
                              </sb:series>
                              <sb:date>2018</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>60</sb:first-page>
                              <sb:last-page>72</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0215">
                     <ce:label>43</ce:label>
                     <sb:reference id="sbref0215">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>X.Y.</ce:given-name>
                                 <ce:surname>Dai</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Nuclear translocation and activation of YAP by hypoxia contributes to the chemoresistance of SN38 in hepatocellular carcinoma cells</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Oncotarget</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>7</sb:volume-nr>
                              </sb:series>
                              <sb:date>2016</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>6933</sb:first-page>
                              <sb:last-page>6947</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0220">
                     <ce:label>44</ce:label>
                     <sb:reference id="sbref0220">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>T.Y.</ce:given-name>
                                 <ce:surname>Zhou</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Inactivation of hypoxia-induced YAP by statins overcomes hypoxic resistance tosorafenib in hepatocellular carcinoma cells</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Sci. Rep.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>6</sb:volume-nr>
                              </sb:series>
                              <sb:date>2016</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>30483</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0225">
                     <ce:label>45</ce:label>
                     <sb:reference id="sbref0225">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Zhu</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Multikinase Inhibitor CT-707 targets liver cancer by interrupting the hypoxia-activated IGF-1R-YAP axis</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Cancer Res.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>78</sb:volume-nr>
                              </sb:series>
                              <sb:date>2018</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>3995</sb:first-page>
                              <sb:last-page>4006</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0230">
                     <ce:label>46</ce:label>
                     <sb:reference id="sbref0230">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Su</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Post-translational modification localizes MYC to the nuclear pore basket to regulate a subset of target genes involved in cellular responses to environmental signals</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Genes Dev.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>32</sb:volume-nr>
                              </sb:series>
                              <sb:date>2018</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1398</sb:first-page>
                              <sb:last-page>1419</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0235">
                     <ce:label>47</ce:label>
                     <sb:reference id="sbref0235">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Han</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Small-molecule MYC inhibitors suppress tumor growth and enhance immunotherapy</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Cancer Cell</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>36</sb:volume-nr>
                              </sb:series>
                              <sb:date>2019</sb:date>
                           </sb:issue>
                        </sb:host>
                        <sb:comment>483–497.e15</sb:comment>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0240">
                     <ce:label>48</ce:label>
                     <sb:reference id="sbref0240">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Mrakovcic</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>p53 at the crossroads between different types of HDAC inhibitor-mediated cancer cell death</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Int. J. Mol. Sci.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>20</sb:volume-nr>
                              </sb:series>
                              <sb:date>2019</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>2415</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0245">
                     <ce:label>49</ce:label>
                     <sb:reference id="sbref0245">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Acetylation-regulated interaction between p53 and SET reveals a widespread regulatory mode</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Nature</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>538</sb:volume-nr>
                              </sb:series>
                              <sb:date>2016</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>118</sb:first-page>
                              <sb:last-page>122</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0250">
                     <ce:label>50</ce:label>
                     <sb:reference id="sbref0250">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>C.L.</ce:given-name>
                                 <ce:surname>Brooks</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Gu</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>The impact of acetylation and deacetylation on the p53 pathway</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Protein Cell</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>2</sb:volume-nr>
                              </sb:series>
                              <sb:date>2011</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>456</sb:first-page>
                              <sb:last-page>462</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0255">
                     <ce:label>51</ce:label>
                     <sb:reference id="sbref0255">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>S.J.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Acetylation is crucial for p53-mediated ferroptosis and tumor suppression</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Cell Rep.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>17</sb:volume-nr>
                              </sb:series>
                              <sb:date>2016</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>366</sb:first-page>
                              <sb:last-page>373</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0260">
                     <ce:label>52</ce:label>
                     <sb:reference id="sbref0260">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>U.</ce:given-name>
                                 <ce:surname>De</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>A new synthetic histone deacetylase inhibitor, MHY2256, induces apoptosis and autophagy cell death in endometrial cancer cells via p53 acetylation</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Int. J. Mol. Sci.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>19</sb:volume-nr>
                              </sb:series>
                              <sb:date>2018</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>2743</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0265">
                     <ce:label>53</ce:label>
                     <sb:reference id="sbref0265">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Zheng</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Inhibiting p53 acetylation reduces cancer chemotoxicity</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Cancer Res.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>77</sb:volume-nr>
                              </sb:series>
                              <sb:date>2017</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>4342</sb:first-page>
                              <sb:last-page>4354</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0270">
                     <ce:label>54</ce:label>
                     <sb:reference id="sbref0270">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>D.S.</ce:given-name>
                                 <ce:surname>Hsu</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Acetylation of snail modulates the cytokinome of cancer cells to enhance the recruitment of macrophages</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Cancer Cell</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>26</sb:volume-nr>
                              </sb:series>
                              <sb:date>2014</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>534</sb:first-page>
                              <sb:last-page>548</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0275">
                     <ce:label>55</ce:label>
                     <sb:reference id="sbref0275">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>O.A.</ce:given-name>
                                 <ce:surname>Nebbios</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>c-Myc modulation and acetylation is a key HDAC inhibitor target in cancer</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Clin. Cancer Res.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>23</sb:volume-nr>
                              </sb:series>
                              <sb:date>2017</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>2542</sb:first-page>
                              <sb:last-page>2555</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0280">
                     <ce:label>56</ce:label>
                     <sb:reference id="sbref0280">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Hamamoto</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Critical roles of non-histone protein lysine methylation in human tumorigenesis</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Nat. Rev. Cancer</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>15</sb:volume-nr>
                              </sb:series>
                              <sb:date>2015</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>110</sb:first-page>
                              <sb:last-page>124</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0285">
                     <ce:label>57</ce:label>
                     <sb:reference id="sbref0285">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>S.T.</ce:given-name>
                                 <ce:surname>Keating</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>El-Osta</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Transcriptional regulation by the Set7 lysine methyltransferase</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Epigenetics</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>8</sb:volume-nr>
                              </sb:series>
                              <sb:date>2013</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>361</sb:first-page>
                              <sb:last-page>372</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0290">
                     <ce:label>58</ce:label>
                     <sb:reference id="sbref0290">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Sarris</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Context-specific regulation of cancer epigenomes by histone and transcription factor methylation</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Oncogene</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>33</sb:volume-nr>
                              </sb:series>
                              <sb:date>2014</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1207</sb:first-page>
                              <sb:last-page>1217</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0295">
                     <ce:label>59</ce:label>
                     <sb:reference id="sbref0295">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>Q.</ce:given-name>
                                 <ce:surname>Liu</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Functional regulation of hypoxia inducible factor-1alpha by SET9 lysine methyltransferase</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Biochim. Biophys. Acta</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>1853</sb:volume-nr>
                              </sb:series>
                              <sb:date>2015</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>881</sb:first-page>
                              <sb:last-page>891</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0300">
                     <ce:label>60</ce:label>
                     <sb:reference id="sbref0300">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Meng</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Discovery and optimization of novel, selective histone methyltransferase SET7 inhibitors by pharmacophore- and docking-based virtual screening</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>58</sb:volume-nr>
                              </sb:series>
                              <sb:date>2015</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>8166</sb:first-page>
                              <sb:last-page>8181</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0305">
                     <ce:label>61</ce:label>
                     <sb:reference id="sbref0305">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>Y.C.</ce:given-name>
                                 <ce:surname>Chae</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>FOXO1 degradation via G9a-mediated methylation promotes cell proliferation in colon cancer</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Nucleic Acids Res.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>47</sb:volume-nr>
                              </sb:series>
                              <sb:date>2019</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1692</sb:first-page>
                              <sb:last-page>1705</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0310">
                     <ce:label>62</ce:label>
                     <sb:reference id="sbref0310">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.A.</ce:given-name>
                                 <ce:surname>Dawson</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>The cancer epigenome: concepts, challenges, and therapeutic opportunities</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Science</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>355</sb:volume-nr>
                              </sb:series>
                              <sb:date>2017</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1147</sb:first-page>
                              <sb:last-page>1152</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0315">
                     <ce:label>63</ce:label>
                     <sb:reference id="sbref0315">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.S.</ce:given-name>
                                 <ce:surname>Seeler</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Dejean</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>SUMO and the robustness of cancer</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Nat. Rev. Cancer</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>17</sb:volume-nr>
                              </sb:series>
                              <sb:date>2017</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>184</sb:first-page>
                              <sb:last-page>197</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0320">
                     <ce:label>64</ce:label>
                     <sb:reference id="sbref0320">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Ablain</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>The drug-induced degradation of oncoproteins: an unexpected Achilles’ heel of cancer cells?</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Cancer Discov.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>1</sb:volume-nr>
                              </sb:series>
                              <sb:date>2011</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>117</sb:first-page>
                              <sb:last-page>127</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0325">
                     <ce:label>65</ce:label>
                     <sb:reference id="sbref0325">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.D.</ce:given-name>
                                 <ce:surname>Kessler</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>A SUMOylation-dependent transcriptional subprogram is required for Myc-driven tumorigenesis</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Science</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>335</sb:volume-nr>
                              </sb:series>
                              <sb:date>2012</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>348</sb:first-page>
                              <sb:last-page>353</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0330">
                     <ce:label>66</ce:label>
                     <sb:reference id="sbref0330">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>He</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Probing the roles of SUMOylation in cancer cell biology by using a selective SAE inhibitor</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Nat. Chem. Biol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>13</sb:volume-nr>
                              </sb:series>
                              <sb:date>2017</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1164</sb:first-page>
                              <sb:last-page>1171</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0335">
                     <ce:label>67</ce:label>
                     <sb:reference id="sbref0335">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Gonzalez-Prieto</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>c-Myc is targeted to the proteasome for degradation in a SUMOylation-dependent manner, regulated by PIAS1, SENP7 and RNF4</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Cell Cycle</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>14</sb:volume-nr>
                              </sb:series>
                              <sb:date>2015</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1859</sb:first-page>
                              <sb:last-page>1872</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0340">
                     <ce:label>68</ce:label>
                     <sb:reference id="sbref0340">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>Y.J.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Allosteric inhibition of ubiquitin-like modifications by a class of inhibitor of SUMO-activating enzyme</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Cell Chem. Biol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>26</sb:volume-nr>
                              </sb:series>
                              <sb:date>2019</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>278</sb:first-page>
                              <sb:last-page>288</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
               </ce:bibliography-sec>
            </ce:bibliography>
         </tail>
      </article>
   </xocs:serial-item></xocs:doc></originaltext></full-text-retrieval-response>